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2ABSTRACT 
The Alternative Oxidase, AOX, is a ubiquitous terminal oxidase of plants and many fungi, 
catalyzing the 4-electron reduction of oxygen to water alongside the cytochrome-based electron 
transfer chain. Unlike the classical electron transfer chain, however, the activity of AOX does not 
generate ATP but has functions such as thermogenesis and stress response. As it lacks a 
mammalian counterpart, it has been investigated intensely in pathogenic fungi. However, it is in 
African trypanosomes, which lack cytochrome-based respiration in their infective stages, that 
trypanosome alternative oxidase (TAO) plays the central and essential role in their energy 
metabolism. TAO was validated as a drug target decades ago and among the first inhibitors to be 
identified was salicylhydroxamic acid (SHAM), which produced the expected trypanocidal 
effects, especially when potentiated by co-administration with glycerol to inhibit anaerobic 
energy metabolism as well. However, the efficacy of this combination was too low to be of 
practical clinical use. The antibiotic ascofuranone proved a much stronger TAO inhibitor and was 
able to cure Trypanosoma vivax infections in mice without glycerol and at much lower doses, 
providing an important proof of concept milestone. Systematic efforts to improve the SHAM and 
ascofuranone scaffolds, aided by the elucidation of the TAO crystal structure, provided detailed 
SAR information and reinvigorated the drug discovery effort. Recently, the coupling of 
mitochondrion-targeting lipophilic cations to TAO inhibitors has dramatically improved drug 
targeting and trypanocidal activity while retaining target protein potency. These developments 
appear to have finally signposted the way to preclinical development of TAO inhibitors.
KEYWORDS: Trypanosome Alternative Oxidase; mitochondrial targeting; structure-aided drug 
design; lipophilic cation; triphenylphosphonium, structure-activity relationship; ascofuranone; 
salicylhydroxamic acid analogues; synthetic strategies
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1. INTRODUCTION
The alternative oxidase (AOX) is ubiquitous throughout the plant kingdom and also common 
among some pathogenic and agrochemically important fungi.1-3 AOX is widespread among 
human parasites such as Trypanosoma brucei (the causative agent of African trypanosomiasis),4 
Cryptosporidium parvum5,6 and Blastocystis hominis (intestinal parasites),2,7,8 and opportunistic 
human pathogens such as the fungus Candida albicans.9 In all of these organisms, AOX plays a 
critical role in their respective life cycles and since the protein is absent from mammals, it has 
become a novel therapeutic target for the treatment of diseases caused by such organisms.
AOX is a membrane-bound ubiquinol oxidase with a heme-free diiron active site that catalyzes 
the cyanide- and antimycin-A-resistant oxidation of ubiquinol and the reduction of oxygen to 
water in a four-electron process.10 Thus, AOX short-circuits the mitochondrial electron-transport 
chain prior to proton translocation by complexes III and IV, thus drastically reducing ATP 
formation.8 In plants, it plays a key role in cellular metabolism, thermogenesis, and energy 
homeostasis.1,11 In T. brucei, a protozoan parasite that causes African trypanosomiasis in humans 
(sleeping sickness)4 and in livestock (nagana)12 throughout sub-Saharan Africa, the trypanosome 
alternative oxidase (TAO) is located in their single mitochondrion and essential for the respiration 
of bloodstream form (BSF) parasites that cause the clinical symptoms and lack the canonical 
oxidative phosphorylation processes.13-17 In effect, in BSF trypanosomes, TAO is the sole terminal 
oxidase enzyme to re-oxidize the NADH that accumulates during glycolysis, and, as TAO has no 
counterpart in mammalian cells and is conserved among T. brucei subspecies,16 it has been 
validated as a promising target for the chemotherapy of African trypanosomiasis.15,18 With 
reference to TriTrypDB (http://tritrypdb.org/tritrypdb/), genes syntenic to T. brucei brucei AOX 
(Tb927.10.7090) are present in other organisms including those causing serious human (T. b. 
gambiense) and veterinary (T. congolense, T. evansi, T. vivax) diseases. However, these are not 
syntenic in T. cruzi and Leishmania spp. Tb927.10.9760 is a truncated, and presumed to be 
inactive form of AOX, and is referred to as AOX2 in Gene DB. It is this gene that is syntenic in 
Leishmania and T. cruzi, but to date its role has been much less studied in those organisms.
Due to its uniqueness and its critical role in the trypanosome’s metabolism, the search for 
clinically effective TAO inhibitors has been on for over 40 years. Nevertheless, there is still no 
TAO inhibitor at an advance stage of clinical development for the treatment of African 
trypanosomiasis, or for any other pathogenic parasite or fungal infection. However, the recent 
elucidation of the TAO 3D-structure by Shiba et al.10 has opened new paths in the search for AOX 
inhibitors and has rekindled interest in this subject as evidenced by the increasing number of 
papers published on this subject in recent years. However, no article has reviewed the state-of-
the-art on the SAR and structure-aided design of TAO inhibitors over the last 40 years. A 
5systematic review of the state of chemistry, SAR and structure-aided design of TAO inhibitors, 
and the recent efforts at improved mitochondrial targeting of the inhibitors, is sorely needed in 
order to progress towards genuine clinical candidates.
Hence, in this review, we address these issues by reviewing the different classes of AOX 
inhibitors reported in the literature since the discovery of the first few inhibitors (e.g. SHAM). 
This will be helpful for researchers working in this re-emerging field, especially since this review 
will for the first time bring all biological data and target validation evidence together with a 
complete overview of the inhibitor design efforts of decades. Since most inhibitors of alternative 
oxidases were developed specifically as TAO inhibitors, this review covers those in particular 
depth, although inhibitors of other AOXs are also included. Furthermore, we address structure-
aided inhibitor design and recent strategies for mitochondrial targeting of the inhibitors that have 
resulted in a major increase in anti-parasite potency. This includes the description of the 3D-
structure of TAO, the development of the ascofuranone pharmacophore, and the synthetic 
strategies to obtain these inhibitors. The perspectives for the clinical implementation of optimized 
TAO inhibitors against African trypanosomiasis and other pathogenic parasites and fungi will be 
discussed.
2. ALTERNATIVE OXIDASES IN HUMAN AND VETERINARY PARASITES
The alternative oxidase, AOX, is a non-protonmotive ubiquinol–oxygen oxidoreductase which 
couples the oxidation of ubiquinol with the reduction of molecular oxygen to water; the enzyme 
is insensitive to inhibitors of the cytochrome oxidase (COX) pathway. While it has long been 
documented as ubiquitous within the plant kingdom, it has also become evident that it is present 
in other organisms including some parasites that causes devastating diseases in humans and 
essential livestock. 
Initially it was observed that medically important apicomplexan parasites including Plasmodium 
falciparum use a cyanide-insensitive AOX-mediated respiration that can be inhibited by AOX 
inhibitors such as propyl gallate (110), 8-hydroxyquinoline (71) and salicylhydroxamic acid 
(SHAM).19,20 Although this observation shows the existence of an alternative pathway of 
respiration in this parasite, it does not offer any information concerning the molecular nature of 
the oxidase involved. Moreover, when the P. falciparum and Toxoplasma gondii genome projects 
were completed and annotated, it did not identify any protein that is similar to those previously 
identified for plants, protozoa or fungi AOXs.21,22 Homologues of AOX have however been found 
in other human parasites including Cryptosporidium parvum.6,23 C. parvum is another 
apicomplexan protozoan parasite that infects humans, causing a diarrheal disease called 
cryptosporidiosis; there is currently no satisfactory chemotherapy available, making it a 
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6potentially fatal disease, particularly in elderly, young and immunosuppressed individuals. It can 
also cause longer-term problems, including stunting in malnourished children.24,25 Suzuki et al.23 
presented the first direct evidence for the presence of a cyanide-insensitive quinol oxidase (AOX) 
in C. parvum. The C. parvum AOX (CpAOX) coding sequence was identified and the full-length 
CpAOX cDNA was cloned, providing AOX sequence from the phylum apicomplexa for the first 
time. Roberts et al.6 also identified and sequenced putative AOX sequences from both type 1 and 
2 strains of C. parvum. The CpAOX genes encode a polypeptide of 336 amino acids having a 
predicted N-terminal targeting sequence similar to those found in proteins targeted to the 
mitochondria of other species. CpAOX was reported to be inhibited by ascofuranone (188)6 and 
the potential of AOX as a novel target for chemotherapy against C. parvum was further 
corroborated by the inhibition of in vitro growth of C. parvum by SHAM (2) and 8-
hydroxyquinoline (71).6 
An AOX has also been reported to be present in other intestinal parasites such as Blastocystis 
hominis2,6-8,23 where it was thought that AOX helps Blastocystis cope with oxygen stress 
conditions in the intestine of the host and avoid the formation of reactive oxygen species.26
The presence of AOX in the opportunistic human pathogen Candida albicans has also been 
reported. Several studies have been conducted in order to further understand the role of AOX in 
Candida albicans. One of such studies is that conducted by Yan et al.,9 which analyzed the effects 
of combinations of antifungal azoles and either the COX inhibitor cyanide or the AOX inhibitor 
SHAM on the mitochondrial respiration. Strains of C. albicans deleted for AOX were also studied 
for susceptibility to azoles and for the generation of intracellular reactive oxygen species (ROS). 
It was observed that the induction of the alternative respiratory pathway by cyanide reduced their 
sensitivity to azoles, while inhibition of the alternative respiration by SHAM drastically increased 
their sensitivity to azoles. This was clear evidence that this fungus expressed both the classical 
cytochrome-mediated electron-transfer chain and an AOX, and that inhibition of either pathway 
hypersensitizes to inhibitors of the other pathway. As such, the combination of SHAM with 
fluconazole (an inhibitor of the cytochrome P450 enzyme 14α-demethylase) displayed a 
synergistic effect against clinical isolates of C. albicans.9 As ROS attained substantially higher 
levels after exposure to antifungals in the absence of AOX than in control cells, it appears that at 
least one function of Candida AOX is the mitigation of oxidative stress.9
AOX has also been identified in African trypanosomes, the causative agent of sleeping sickness 
(or human African trypanosomiasis (HAT)) and the various species causing animal African 
trypanosomiasis (AAT) including Trypanosoma vivax27 and Trypanosoma brucei.14,16 Several 
Trypanosoma species and subspecies are of great medical or economic concern on the African 
continent where they cause HAT and/or AAT, affecting cattle rearing and agricultural 
Page 6 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
7development in resource-poor communities.12,28,29 Two subspecies of Trypanosoma brucei infect 
humans, each causing slightly different pathologies, both almost invariably lethal, although there 
are emerging, sporadic reports of long-term asymptomatic cases.30 Trypanosoma brucei 
gambiense is found in central and western Africa where it causes a relatively chronic form of the 
disease which may develop over a number of years. T. b. rhodesiense on the other hand is found 
in southern and east Africa where it causes an acute illness that could lead to death within 
weeks.14,16,31
Even though these trypanosomes and their vector are localized to Africa, imported human cases 
in Europe are well documented,32,33 and the veterinary form of trypanosomiasis has spread to 
become a major economic issue from Southern Asia to much of South America, as species such 
as Trypanosoma equiperdum, T. evansi and T. vivax have adapted to tsetse-independent 
transmission modes, fatally infecting high value animals such as horses, camels, cattle and water-
buffalo.12 
2.1. Origin of the plant-like alternative oxidase of trypanosomes
Investigations into the cyanide-resistant respiration of plants lead to the discovery of the second 
terminal oxidase in the mitochondrial respiratory chain called the alternative oxidase. AOX was 
first identified in plants in the 1920s34,35 and it has since been thoroughly researched. Indeed, most 
of the information we have about the AOX class of proteins today is as a result of the intensive 
research carried out on alternative oxidases from plants. 
Genes encoding AOX are ubiquitous in the Kingdom Plantae, where the enzyme plays a crucial 
role in thermogenesis, cellular metabolism, and energy homeostasis; it is also generally believed 
to be a major stress-induced protein.1,11 For instance, a small group of “thermogenic” plants were 
able to maintain a very high rate of uncoupled, and hence heat-releasing AOX respiration, thereby 
heat-up their reproductive tissues to temperatures that are well above ambient.36-38 This provides 
the needed optimal temperatures for floral development or simply serves to attract pollinators. 
Nevertheless, most plants are intrinsically non-thermogenic, in which case the expression of the 
AOX gene in them must be for other purposes. Indeed, AOX play crucial roles in plants but its 
function varies, depending on the type of plant and its physiological state. The activity of AOX 
optimizes the process of photosynthesis,11 by ensuring that the redox balance in the cell is 
maintained. Substantial amounts of reductants are generated during photosynthesis, which, when 
allowed to accumulate, would lead to the process of photo-inhibition in the chloroplasts. These 
excess reductants are exported from the chloroplasts to the mitochondria, where they are oxidized 
in the electron transport chain non-phosphorylating pathway.39 
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8The activity of AOX is also significant when certain environmental conditions or metabolic 
processes produce cytochrome oxidase (COX)-inhibiting compounds, which decrease the activity 
of the COX pathway. Examples are nitric oxide (NO), which is produced in plants that are under 
stress conditions;40-42 cyanide, which is produced upon increased synthesis of ethylene in plants;43 
and hydrogen sulphide (H2S), which is produced in the process of detoxification of endogenous 
cyanogenic compounds by β-cyanoalanine synthase.43 Phosphorus deficiency in some plants is 
another example of environmental conditions that can limit the activity of the COX pathway, as 
inorganic phosphorus (Pi) is necessary for ATP synthesis, and increased ADP levels suppress the 
COX pathway and consequently increase AOX activity.44
The study of plant AOX paved the way for the identification of alternative ways of respiration in 
protozoa including pathogenic organisms such as Trypanosoma brucei.14,45,46 
The trypanosome was first discovered in 1895 by Sir David Bruce as the etiological agent of the 
cattle disease nagana.47,48 T. brucei, like most pathogenic parasites undergo various lifecycle 
changes and have developed a range of physiological functions that are indispensable for their 
survival within the specialized environment of the insect (tsetse fly) vector and/or mammalian 
host. For instance, they adapt to a low oxygen tension in their host using diverse metabolic 
pathways that are quite distinct from those of their host. The parasite’s mitochondrion undergoes 
substantial changes in its composition and morphology as a result of this environmental and 
development adaptation.15
The parasite lives as the bloodstream form (BSF) in the mammalian host and as the procyclic 
form in the tse-tse fly vector; in whichever form it exists, it is well equipped for its environment, 
with unique energy metabolism. The procyclic form, for instance, meets its ATP synthesis 
requisite from a cyanide-sensitive and cytochrome-dependent respiratory chain similar to that 
present in the mitochondria of mammalian cells,45 whereas no significant expression of 
cytochromes has been reported in the long-slender BSF of the parasite living freely in the blood 
of the mammalian host. Yet, BSF respire at a very high rate; their glucose consumption rate is 
100-fold higher than that of the procyclics or their mammalian host cells.14,49,50 In 1960, Grant 
and Sargent discovered the glycerol-3-phosphate oxidase system (GPO) as the unique enzyme 
system responsible for this type of respiration.51
At least two enzymes were reported to be contained in the GPO: a glycerol-3-phosphate oxidase 
and glycerol-3-phosphate dehydrogenase.50,51 Using isopycnic sucrose gradient centrifugation, 
Opperdoes and his co-workers established for the first time, that GPO is present in the same 
fraction as all the other mitochondrial enzymes, such as malate dehydrogenase, oligomycin-
sensitive ATPase, and isocitrate dehydrogenase.52
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9Following this discovery, Fairlamb and Bowman reported the partial purification of the 
holoenzyme complex from T. brucei,53 showing that the glycerol-3-phosphate dehydrogenase 
component has FAD as cofactor. Afterwards, Clarkson and his co-workers17 established that the 
dehydrogenase component of the GPO system is connected to the terminal oxidase via the 
coenzyme Q9. Consequently, the oxidase component of GPO is a ubiquinol oxidase, which 
transfers electrons to molecular oxygen. It was also revealed at the time, that the electron transfer 
via the terminal oxidase was not coupled to the translocation of protons or to ATP production in 
the mitochondria.17 These findings contributed to the discovery of the first specific inhibitors of 
GPO, salicylhydroxamic acid (SHAM) and ascofuranone.17,54,55 Considering the similarities 
observed between the T. brucei GPO and AOX from higher plants, and because ubiquinol was 
eventually identified as the substrate (instead of glycerol-3-phosphate), the trypanosome GPO 
was eventually renamed as the trypanosome alternative oxidase (TAO) by Clarkson and his co-
workers,17 and this name has now been widely accepted by all researchers in this field.
Using antibodies previously raised against the AOX from the flowering plant Sauromatum 
guttatum, Chaudhuri et al.56 identified TAO as a 33 kDa protein in the mitochondria of T. brucei, 
which was successively purified from the mitochondria of BSF and confirmed to have ubiquinol 
oxidase activity. TAO is approximately 100-fold higher expressed in BSF than in procyclic T. 
brucei,16 as the latter form expresses complexes III and IV and is capable of synthesizing ATP 
through oxidative phosphorylation, whereas the BSF depend solely on TAO for respiration. 
In 1996, Chaudhuri and Hill identified a single copy TAO gene (Tb927.10.7090) following their 
successful design of primers for the cloning of TAO from gDNA of T. brucei, using areas of high 
conservation found in plant AOXs. This enabled its recombinant expression in E. coli, which was 
instrumental in the characterization of its kinetic parameters and of course the screening for 
inhibitors.57 However, this research was initially hampered by the presence of endogenous 
ubiquinol oxidase activities in native E. coli, in the form of the cytochrome bo and bd complexes. 
This was overcome by overexpression of rTAO in a ΔhemeA mutant E. coli (FN102), which is 
unable to synthesize the heme needed for cytochrome assembly. In addition to further refinements 
in the production, solubilization and purification of rTAO has enabled high quality kinetic, 
structural and inhibitor studies.10,45
The AOX gene of T. brucei contains 990 nucleotides encoding the 330 amino acids full length 
protein, including the predicted N-terminal Mitochondrial Targeting Signal (MTS) of 25 amino 
acid residues. As the MTS is cleaved off after transportation of the protein to the mitochondrion, 
the physiologically functional and relevant form of TAO is lacking the MTS sequence.58 
However, until recently only the full-length protein had been produced and studied by the various 
authors, despite difficulties associated with its stability, solubility and yield,10,45,59-61 and although 
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10
it is clearly desirable to conduct inhibitor studies with the physiologically relevant form of the 
protein. When a ΔMTS rTAO, lacking the first 75 nucleotides, was produced it was found to have 
relatively higher activity, solubility and stability compared to the full-length enzyme.13,62 
2.2. Role of TAO in trypanosome metabolism
2.2.1. TAO is essential for bloodstream form respiration 
Biochemical studies have shown that TAO is bound to the mitochondrial inner-membrane and 
catalyzes the cyanide- and antimycin-A-resistant, non-protonmotive oxidation of ubiquinol, and 
the associated four-electron reduction of molecular oxygen to water. This type of respiration 
short-circuits the mitochondrial electron-transport chain before proton translocation by 
complexes III and IV, thus severely reducing ATP formation.1,2,34,45,63I It is only physiologically 
possible because bloodstream trypanosomes, having direct access to an inexhaustible supply of 
glucose, produce enough ATP by glycolysis alone.
TAO expression occurs at almost all stages of the T. brucei life-cycle, but the level of expression 
is developmentally regulated as the functionality of TAO depends on the developmental stage of 
the parasite. For instance, in the tsetse fly, TAO is expressed at a low level to allow for respiratory 
plasticity which helps the parasite survive the very harsh environment in the midgut of the fly;14 
however, these procyclic forms have a fully functional electron transport chain, and express TAO 
together with COX and all the tricarboxylic acid (TCA) cycle proteins. Conversely, the BSFs 
present in the mammalian hosts do not express COX or most TCA cycle proteins,50,64 and their 
mitochondria do not contain the succinate dehydrogenase complex (complex II)28 or use the 
classical electron transport chain to generate the proton-motive force over the inner mitochondrial 
membrane.65,66 Instead, TAO is up-regulated through a post-transcriptional mechanism and the 
parasite relies exclusively on TAO as the sole terminal oxidase in its mitochondrial electron 
transport chain. The post-transcriptional nature of the up-regulation ensures that although the 
steady-state level of TAO mRNA in the parasite is only five-fold greater, the TAO protein level 
is approximately 100-fold greater than that of the procyclic form.67
This arrangement means BSF rely solely on the catabolism of blood glucose, taken up efficiently 
by the THT1 transporter,68 as its source of energy50 and in order to ensure the required high 
glycolytic flux the trypanosome developed a unique organelle, the glycosome, which is the 
compartment where glycolysis takes place.69 This organelle contains a 100-fold higher 
concentration of glycolytic enzymes compared to the cytoplasm of a typical cell, allowing the 
glycolytic reaction to take place with high efficiency, with pyruvate as its end product, which is 
normally secreted by the parasite, through a Pyruvate Transporter (TbPT0) that is related to a 
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plant gene family rather than mammalian carboxylate transporters.70 The glyceraldehyde 
dehydrogenase (GAPDH) step of glycolysis generates reducing equivalents in the form of NADH, 
which must be re-oxidized to NAD+ and this requires the regeneration of dihydroxyacetone 
phosphate (DHAP) from glycerol-3-phosphate (G-3-P).71 During this process, Glycerol-3-
phosphate dehydrogenase (G-3-PDH) oxidizes G-3-P to DHAP, facilitating the transfer of 4 
electrons to ubiquinol,14 which is subsequently oxidized to ubiquinone by TAO to convert 
molecular oxygen to water (Figure 1a). Thus, under aerobic conditions, a molecule of glucose in 
the BSF produces a net yield of just two molecules of ATP, as no ATP is generated by the 
electrons transferred to TAO. 
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Figure 1. A scheme of aerobic (a) and anaerobic (b) glycolysis in bloodstream-form 
Trypanosoma brucei. The solid lines represent reactions catalysed by a single enzyme, whereas 
the dashed lines represent multiple sequential reactions. G-6-P = glucose-6-phosphate; F-1,6-BP 
= fructose-1,6-bisphosphate; GA-3-P = glyceraldehyde-3-phosphate; 1,3-BPG = 1,3-
bisphosphoglycerate; 3-PG = 3-phosphoglycerate; DHAP = dihydroxyacetone phosphate; G-3-P 
= glycerol-3-phosphate; 1 = Glycerol-3-phosphate dehydrogenase; 2 = Glycerol kinase; 3 = 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH); 4 = Glycerol-3-phosphate dehydrogenase 
(G-3-PDH).
Conversely, under anaerobic condition or when TAO is inhibited by inhibitors such as SHAM or 
ascofuranone, only one mole of ATP per mole of glucose is produced as G-3-P can no longer be 
reformed to DHAP, leading to the production of equimolar amounts of pyruvate and glycerol as 
waste products to be released (Figure 1b).14 Although this halves its energy production to a single 
ATP/glucose, BSF can survive these conditions for short periods, as the conversion of G-3-P to 
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glycerol by the enzyme glycerol kinase (GK) ensures that the glycosomal NAD+/NADH balance 
is maintained. This means that the inhibition of TAO alone is not sufficient to rapidly kill the BSF 
although T. brucei cultures were sterilized by SHAM within 24 h,72 due to the accumulation of 
glycerol in the medium. Once a millimolar concentration of glycerol is attained, the reverse action 
of glycerol kinase will dominate, due to mass action of glycerol, producing G-3-P from glycerol, 
leading to a halt of the anaerobic glycolysis taking place in the glycosome.73 Indeed, co-
administration of 0.5 mM glycerol with SHAM or ascofuranone (a TAO inhibitor) led to an 
immediate death and disappearance of the parasites from the blood of T. vivax-infected mice.74 
Helfert et al.72 also saw that reducing TAO expression with RNAi killed the parasites. These 
results show that TAO is essential for the respiration of BSF T. brucei. Over-production of TAO 
protein in the procyclic form causes a preferential shift from COX-mediated respiration to TAO-
mediated respiration75 but the attempted overexpression of the TAO in BSF did not appear to 
yield a significant increase in TAO protein, or a shift in inhibitor EC50 values; this was attributed 
to the already very high level of TAO in these cells.13 
2.2.2. The role of TAO in procyclic trypanosomes: control of ROS and surface coat 
composition
One of the major roles of the AOX in photosynthetic plants is to protect the photosynthetic 
machinery from reactive oxygen species (ROS) through the rapid turnover of NADH. Maxwell 
and co-workers discovered that the overexpression of AOX resulted in cells with lower ROS 
levels.41 Several studies have suggested that TAO similarly protects trypanosomes against 
ROS.15,18,76 For instance, Fang and Beattie76 found that inhibiting TAO with SHAM elevates the 
levels of ROS in the mitochondria of procyclic trypanosomes, causing increased oxidative 
damage to cellular proteins. Conversely, inhibiting the cytochrome bc1 complex with antimycin 
A, or treating cells with hydrogen peroxide (either of which increases cellular ROS levels), 
resulted in increased expression and activity of TAO.76 The possibility that TAO acts to prevent 
damaging oxidative stress by ROS has not been extensively studied in the long-slender 
bloodstream form of T. brucei, where its role in respiration is of primary importance; however, 
TAO-mediated ROS protection has been suggested to inhibit programmed cell death (PCD)-like 
phenomena in BSF T. b. rhodesiense under stress conditions such as high cell density or cold 
temperature.77 
The surface of the procyclic form of T. brucei that resides in the midgut of tsetse flies is covered 
by several million copies of invariant glycosylphosphatidylinositol-anchored proteins known as 
procyclins. They are the products of a small multigene family known to encode unusual proteins 
containing an extensive tandem repeat unit of characteristic amino acid sequences at the C 
terminus. It has been suggested that procyclins protect the procyclics against proteases and/or 
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participate in tropism, which directs the parasites from the tse-tse fly midgut to its salivary glands 
prior to transmission to a new host.78,79  The two major types of procyclin are GPEET and EP, 
which contain an internal pentapeptide repeat motif (rich in Gly-Pro-Glu-Glu-Thr repeats), and a 
dipeptide internal repeat motif (rich in Glu-Pro repeats), respectively. 
The expression of GPEET and EP in T. brucei is developmentally regulated in the tsetse fly 
midgut, with the GPEET component downregulated in late procyclics.80 Vassella et al.81 showed 
that the inhibition of TAO activity by SHAM in procyclics of T. brucei repressed the expression 
of GPEET procyclin, whereas repression of the pyruvate dehydrogenase or succinyl-CoA 
synthetase boosted GPEET expression in late procyclics. Similarly, the overexpression of the 
TAO protein was shown to increase GPEET expression.75 Thus, the balance between cytochrome- 
and TAO-mediated respiration, and the associated differences in ROS-protection, appears to 
directly regulate the expression of cell-surface glycoproteins.
2.3. Alternative oxidases in pathogenic and agrochemically important fungi
While AOX is essentially ubiquitous within the plant kingdom, it is also found, although more 
sporadically, in the other kingdoms. AOX has been found in yeasts, algae, free-living amoebae, 
slime molds, nematodes, protists, mollusks, a few animal species (but not mammals), bacteria 
(but not Archaea), as well as fungi.46,57,82-84 In prokaryotes, AOX is restricted to some α-
proteobacteria such as Novosphingobium aromaticivorans,85 and it is probable that AOX entered 
eukaryotic ancestries through the ancient proteobacterial endosymbiont that gave rise to 
mitochondria.3,11 Although this oxidase is thus present in many organisms, its function may vary: 
in thermogenic plants, AOX activity is linked with the production of heat; in other organisms 
AOX activity is essential for ROS control, and for the maintenance of metabolic homeostasis such 
as carbon metabolism, cellular energy demand and redox state.
AOX has been studied intensely in some human-infective fungi, as well as some agrochemically 
important fungi such as Magnaporthe grisea (rice blast fungus) and Chalara fraxinea (U.K. 
dieback Ash disease).1-3 For instance, when certain phytopathogenic fungi were exposed to 
commercial fungicidal agents that targeted their mitochondrial bc1 complex, they expressed a 
plant-like AOX, apparently as an alternative respiratory mechanism, which conferred a degree of 
fungicide resistance on these pathogens.2,86. For example, AOX was induced in M. grisea after 
treatment with the cytochrome bc1 complex inhibitor SSF-126 ((E)-2-methoxyimino-N-methyl-
2-(2-phenoxyphenyl)-acetamide),87 as well as by hydrogen peroxide;88 the expression levels 
correlated with the activity of AOX-mediated respiration. As treatment of M. grisea mitochondria 
with SSF-126 induced the generation of superoxide,87 it is possible that this respiratory inhibitor 
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and peroxide similarly induce AOX expression through the production of ROS, with AOX acting 
in response to oxidative stress. 
Indeed, it is becoming clear that, in numerous fungi, AOX plays a crucial role in the response of 
cells to various types of stress. This conclusion is based mainly on observations of increased AOX 
transcripts during e.g. oxidative stress in Aspergillus niger,89 A. fumigatus,90 Magnaporthe 
grisea,88 Hansenula anomala,91 Candida albicans,9 Paracoccidioides brasiliensis;92 after heat 
shock in Yarrowia lipolytica and Aspergillus niger;89,93 and during osmotic stress in A. niger.89 In 
pathogenic fungi such as P. brasiliensis94 and Cryptococcus neoformans,95 virulence decreased 
upon deletion of the AOX gene, suggesting a significant role for this enzyme during infection.
The hypothesis that AOX is needed for pathogenicity in many of the economically most important 
fungi was also studied in Ustilago maydis, a dimorphic fungus of the phylum basidiomycetes that 
infects maize.96,97 U. maydis depends on mitochondrial function for ATP synthesis.98,99 Cárdenas-
Monroy et al.100 found that AOX expression in this fungus was induced during the stationary 
phase, signifying an important role for AOX at high cell densities, when the nutrients become 
limiting. However, using AOX overexpressing and AOX null U. maydis, it was concluded that 
AOX was dispensable for the normal biology of this fungus, even though essential in the response 
to respiratory stress. 
Given the important cellular functions of AOX in fungi, and its major roles in pathogenicity and 
drug resistance, further research in this area, including the development of inhibitors specific for 
fungal AOXs, would appear to be a priority. The possibility of treatment combining traditional 
fungicides with such inhibitors deserves particular attention.
3. VALIDATION OF TAO AS DRUG TARGET IN AFRICAN TRYPANOSOMES 
A recent trend in drug discovery is that some pharmaceutical companies have shifted away from 
high throughput screening (HTS) for the development of novel therapeutics, to a rational drug 
discovery (RDD) approach.101 RDD is a high-tech approach to drug development that usually 
entails using the 3-dimensional structure of a particular drug target molecule (often a protein) for 
the design of a small effector molecule (an inhibitor/activator or an agonist/antagonist) to affect 
the function of the target molecule in the organism, and bring about a desired therapeutic effect. 
As prerequisites in the early stage, it is important to identify the drug target and to validate that it 
is worthy and druggable, i.e. that its function can be modulated by a drug to elicit a desired 
therapeutic response. The process of target validation assesses whether a molecular target merits 
the development of pharmaceuticals for therapeutic application.102 Certain criteria are used for 
the assessment of a suitable drug target. In the context of African trypanosomiasis, as is the case 
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for most infectious diseases, a good drug target should be essential for the parasite survival (or 
proliferation) in the host and, preferably, absent or not essential to the host (although the latter 
obstacle can be overcome with agents of sufficient specificity for the pathogen target). The 
trypanosome alternative oxidase fulfils these criteria, as it is central to ATP synthesis in the 
bloodstream forms of African trypanosomes and no homolog of the gene is present in 
mammals.14,103
3.1. Validation and functional expression studies
The AOXs of plants are encoded mostly by multigene families and differential expression of the 
separate gene products varies with growth conditions, which regulate their expression at specific 
developmental stages, and in response to external stressors such as fungal pathogens, heat and 
drought.104,105,106 In contrast, TAO is probably a single copy gene  in the genome of African 
trypanosomes, but in a similar fashion its expression level changes dramatically as the parasites 
encounter different environmental conditions in the course of their life cycle. The gene is 
upregulated while the trypanosome is in the mammalian blood but is turned low as they transit to 
the insect-stage procyclic forms, as discussed in section 2.2.2. The functionality of TAO as a 
terminal oxidase was demonstrated in hemA-deficient bacteria, which lack the canonical terminal 
oxidase activity of cytochromes bo or bd due to their inability to synthesize heme.107,108 For these 
mutant bacteria strain to grow, the growth medium must be supplemented with 5-aminolevulinic 
acid (ALA) to bypass the hemA function and enable the bacteria to produce the heme required 
for the cytochrome activities. Growth of the mutant bacteria in the absence of ALA was restored 
when complemented by functional expression of the TAO gene, and was sensitive to SHAM and 
ascofuranone (AF) but insensitive to cyanide.109,110  
It is clear that there is sufficient pharmacological evidence for the essentiality of TAO, however, 
all attempts to knockout even one copy of the TAO genes have been unsuccessful. Nevertheless, 
Helfert and colleagues could achieve a considerable reduction in the level of the corresponding 
mRNA by expressing a homologous double-stranded RNA (TAO dsRNA) using inducible RNA 
interference (RNAi). After 48 h induction of TAO-targeted dsRNA expression, the analogous 
mRNA virtually disappeared resulting in reduction of the growth rate by half, and oxygen 
consumption rate was reduced by fourfold. As expected, the mutants were more susceptible to the 
trypanocidal effect of SHAM than the controls.72 
Knockout of all copies of the TAO genes would provide direct genetic evidence about the 
essentiality of TAO but the repeated failure to achieve this to date strongly suggests that this may 
be impossible, at least without additional adaptations, and that complete loss of TAO is indeed 
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lethal to the trypanosome. An obvious explanation for this would be that the TAO is absolutely 
critical for respiration in T. brucei as shown by all the pharmacological evidence.
3.2. In vitro studies with early inhibitors
The earliest method of in vitro testing of drugs on African trypanosomes relied heavily on the use 
of Tobie’s medium, which is a biphasic culture method that involves transfer of the parasite cells 
into a secondary medium requiring addition of heat inactivated defibrinated blood. Effect of the 
drugs was evaluated microscopically.111,55 This has been replaced by the use of simpler and more 
economic monophasic culture method in which the parasites are maintained in all-liquid medium, 
Hirumi's modified Iscove's medium 9 (HMI-9) supplemented with 10% fetal bovine serum, at 37 
°C and in a 5% CO2 atmosphere.112 Drugs in appropriate vehicles such as phosphate buffered 
saline, dimethyl sulfoxide or ethanol are added to cultures in wells of microtiter plates and 
incubated for a pre-determined period after which the proportion of surviving cells can be 
estimated by direct count under the microscope113 or using a chromogen such as resazurin (Alamar 
blue), which is bio-activated by enzymes in living cells.114,115 The conversion of the resulting 
metabolite resorufin is quantified spectrophotometrically or fluorometrically and it is proportional 
to the number of living cells.116 After the discovery by Schonbaum et al.117 that m-
chlorobenzhydroxamic acid (m-CLAM, 9) was the most potent inhibitor of the cyanide-
insensitive respiratory pathway of plants, Evans and Brown55 reported that it also displayed 
inhibitory activity against the cyanide-insensitive respiration of African trypanosomes. They 
utilized the biphasic culture method to test the anti-trypanosomal potency of m-CLAM and 
recorded that it killed the parasites by specifically blocking the cyanide-insensitive respiration in 
BSFs. Interestingly, high concentrations of m-CLAM effectively killed monomorphic long-
slender BSFs with 100% potency but spared some of the parasites of pleomorphic culture, 
implying that the inhibitor has a very low effect on the cyanide-sensitive respiration that is 
becoming expressed in the short-stumpy bloodstream forms that are pre-adapted for uptake by 
the tsetse fly vector (but also still express high levels of TAO).118 Therefore, m-CLAM was the 
first inhibitor of TAO shown to possess anti-Trypanosoma activity, although the potency is very 
low as up to 3000 µM is required for the complete killing of the parasites in a time period of 20 
minutes.55 This concentration is too high for investigation in animal models because at such high 
concentration, hydroxamic acids also start to inhibit the conventional cyanide-sensitive 
respiration, which is the main energy metabolism pathway in animals.117 A few years later, 
Opperdoes and co-workers found a more potent hydroxamic acid derivative, SHAM.119 At a 
concentration of 1000 µM, SHAM completely (>99%) inhibited TAO and blocked aerobic 
respiration in African trypanosomes but ATP synthesis and parasite motility did not follow the 
same pattern as ATP was detectable and a substantial population of the parasites remained 
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actively motile. However, a complete shutdown of the ATP synthesis and motility was recorded 
when SHAM was combined with 5 mM glycerol,120,121 implying that the inhibition of TAO would 
be therapeutic only in the presence of a high concentration of glycerol. The inhibition constant Ki 
of SHAM for respiratory arrest of trypanosomes was estimated as 29 µM, and 500 µM was 
required for the effective killing of the parasites,122,123 initiating a search for more potent TAO 
inhibitors that could be used for drug development. As a result, several hydroxamic acid 
derivatives were prepared and screened for enzyme inhibition and in vitro trypanocidal activity124 
of which p-n-tetradecyloxybenzhydroxamic acid (57) was found to be the most potent. Compound 
57 displayed over 70-fold better inhibitory potency against the enzyme (Ki = 0.43 µM) and 400 
times greater trypanocidal activity when compared to SHAM.123,125 Recent efforts have led to the 
discovery of more potent compounds with potencies several thousands of times more potent than 
SHAM.13,113,126
3.3. Studies with TAO inhibitors in in vivo models of African trypanosomiasis 
The preclinical phase of drug development requires that the identified drug candidates be tested 
in animal models for further investigations on physiological efficacy and safety. With respect to 
the TAO inhibitors reported to date, the in vivo experimental models that have been used are 
laboratory mice and rats, and goats. Fundamentally, co-administration of TAO inhibitors with 
glycerol is required for the chemotherapy of African trypanosomiasis in animals.120,127,121,128-130 
The treatment outcomes reported from studies with SHAM and derivatives are complicated owing 
to drug- and parasite-related factors. The drug-associated factors include high therapeutic 
dosages, low solubilities, toxicity of the compounds at high dose, and their pharmacokinetics 
(blood concentration of SHAM and glycerol declines rapidly). The parasite-related factors are (1) 
the level of parasitemia before commencement of treatment, (2) ability of the parasites to exist in 
both monomorphic and pleomorphic forms, and (3) abilities of the parasites to reversibly migrate 
from the circulation to other niches and organs such as the brain, testes and adipose tissue.131-133 
The therapeutic dosage of SHAM plus glycerol is impractically and dangerously high. Van der 
Meer et al. reported that doses of 355 mg/kg SHAM plus 1216 mg/kg body weight glycerol, 
respectively,134 which resulted in plasma concentrations of 2 and 20 mM, respectively, cleared T. 
vivax parasitaemia in goats but had severe toxic effects included the deaths of some of the treated 
animals.134 Moreover, as a result of the poor solubility of SHAM, large volumes of up to 1 L of 
the drug mixture solution are required for the treatment of goats. At therapeutic dosage, animals 
(goats, rats and mice) infected with different species of African trypanosomes were cured 
although variations were recorded in the degrees of cure. While goats infected with T. vivax 
eventually relapsed after apparent cure,134 mice that were infected with different strains of 
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trypanosomes were permanently cured.135 Infection of animals with monomorphic bloodstream 
forms resulted in complete cure127,135 but failures were recorded when animals were infected with 
pleomorphic trypanosome strains,136 despite initial clearance of parasitaemia.136 It could be argued 
that these treatment failures could be due to the presence of short-stumpy forms, which also 
express the cytochrome-dependent (SHAM-insensitive) respiration, but this is unlikely as these 
forms are in irreversible growth arrest until they can transform into procyclics in the tsetse fly.118 
However, the pleomorphic cell lines may have a higher preference for extravascular niches where 
the drug concentration may not reach the therapeutic level. 
The low solubility and toxicity of SHAM has stimulated the design of SHAM derivatives that are 
more potent, less toxic and display improved solubility (see section 4).62,126 Likewise, efforts to 
find alternative TAO inhibitors has led to the discovery of ascofuranone (AF),113 and its safety 
and efficacy has been tested in mice infected with African trypanosomes.74,137 Remarkably, 
treatment with AF does not require the intravenous route, and can administered intraperitoneally 
or orally, both of which were able to clear parasitaemia after 30 min and 180 min, respectively, 
in the presence of glycerol. Complete elimination of the T. b. brucei was achieved with 25 mg/kg 
AF and 1000 mg/kg glycerol via the IP route or with 100 mg/kg AF and 1000 mg/kg glycerol for 
the oral route.137 However, AF was also able to cure T. vivax-infected mice without co-
administration of glycerol, as a single i.m. dose of 50 mg/kg or 6 mg/kg i.m. on 4 consecutive 
days.74
3.4. Production of TAO using recombinant DNA technology
Structural elucidation of a particular drug target protein molecule has the potential to greatly 
accelerate the success of drug discovery efforts. Protein X-ray crystallography is a major 
technique that is used for the determination of protein structure, and a major limitation is the 
ability to obtain sufficient quantities (often milligram order) of the isolated, pure protein. It is 
practically impossible to obtain sufficient amounts of most proteins directly from eukaryotic cells, 
and this was a major problem until after recombinant DNA (rDNA) technology was invented in 
the early 1970s,138,139,140 allowing the efficient production of eukaryotic proteins in bacteria. 
TAO is one of the at least 72 proteins found in the mitochondrial membrane sub-fraction of 
African trypanosomes (estimation, based on the presence of at least one predicted transmembrane 
domain in each protein)141 and it is localized in the inner membrane.10 These parasites contain one 
mitochondrion per cell.142 Therefore, the yield of even partially purified TAO obtainable from 
large-scale cultures of the parasites was very low (0.2 mg)56 and insufficient for RDD. Hence, 
rDNA technology was adopted for the production of recombinant TAO (rTAO) for structural 
studies. After the T. b. brucei TAO gene was identified by Chaudhuri et al,57 it was cloned into 
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the pET15b plasmid vector and used to transform FN102 E. coli strain for overexpression, and 
purification of the protein.109,143 This also enabled the expression of hexahistidine-tagged rTAO 
carrying a thrombin cutting site,143,144 both features facilitating the purification of rTAO. 
Being a terminal oxidase, the activity of TAO is similar to those of E. coli cytochromes bo and 
bd complexes, which are expressed for respiratory proton pumping during aerobic and anaerobic 
conditions, respectively.107,107 The presence of these two respiratory enzymes in the E. coli 
expression host for TAO will interfere and complicate the enzymatic assay during the downstream 
analyses for TAO expression. To solve this problem, the quinol oxidase activity of the expression 
host was ablated by blocking the synthesis of the enzymes’ cofactor, heme. This is achieved by 
deletion (through P1 transduction) of the gene that encodes glutamyl-tRNA reductase,145 the 
enzyme that catalyzes the first step of heme biosynthesis in E. coli. The ubiquinol oxidase activity 
of TAO is heme-independent, therefore it is functionally expressed in the resultant heme-deficient 
mutant E. coli strain - in fact, the strain is only able to grow because rTAO functions as the sole 
terminal oxidase in the respiratory chain of the mutants, complementing the heme-deficiency. The 
mutant cells not complemented with TAO can only grow when the culture is supplemented with 
ALA, an early precursor of heme synthesis upstream of glutamyl-tRNA reductase. 
TAO consists of 330 amino acid residues and its N-terminal 25 residues 
(MFRNHASRITAAAAPWVLRTACRQK) form the mitochondrial targeting signal (MTS), 
which is cleaved off after it has entered the mitochondrion, creating ΔMTS-rTAO.58 Until recently 
all studies used expression of full-length rTAO (FL-rTAO), i.e. including the MTS,61,109,144,146 but 
this may not accurate reflect the activity or pharmacology of ΔMTS-rTAO. Therefore, FL-rTAO 
and ΔMTS-rTAO were recently overexpressed and purified under the same conditions and it was 
found that the later presented 2- to 4-fold better properties in terms of solubility, protein yield, 
and specific activity,13 implying that the MTS may affect protein folding, and we strongly 
recommend the use of ΔMTS-rTAO for studies leading to RDD. Residues 1-30 were not visible 
in the crystal structures of TAO because of the flexibility of that sequence,10 reinforcing the 
argument that the splicing off does not substantially affect the catalytic core domains.
Cellular fractionation shows that rTAO localizes in the membrane fraction of the expression host 
and membrane solubilization is therefore an important step in the purification of rTAO. This 
requires the use of an appropriate detergent that will release the enzyme from the membrane 
without negative consequences. Earlier, the detergent NP-40 was used56 but it is associated with 
certain undesirable effects on the enzyme. As a result, Kita’s group performed screening of 
alternative detergents including those that have been reported to work well for plant AOXs, and 
found digitonin to be better in terms of maintaining rTAO stability.144 Further optimization was 
necessary because the yield of rTAO was very low: only 0.38 mg was obtainable from 10 liters 
Page 19 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20
of culture.144 After a further series of screening and optimization, 1.4% (w/v) of n-octyl-β-D-
glucopyranoside (OG) was described to be better at maintaining the protein’s activity and 
improving the yield, which increased to 5-9 mg/10 L culture (Table 1). The OG was changed to 
0.042% (w/v) n-dodecyl-β-D-maltopyranoside during the elution step of the purification.13,61,45
Table 1. Effect on the solubilization detergent on the TAO activity and recovery of purified TAO. 
OG = n-octyl-β-D-glucopyranoside
Detergent
 
TAO yield
(mg/10 L)
Specific activity
(mole/min/mg)
Recovery
(%)
Reference
 
1% Digitonin 0.378 41.5 3.1 Nihei144
1.4% OG 8.95 207 13.2 Kido45
4. PROGRESS IN CHEMICAL SCAFFOLDS AND AOX INHIBITOR DEVELOPMENT
Diphenylamine (1) was the first molecule reported to inhibit the cyanide-insensitive respiratory 
pathway in various plant systems.147,148 This compound was later found to inhibit oxygen uptake 
in bloodstream forms of T. brucei,149 a result that was confirmed a few years later by Clarkson et 
al who reported a low activity (Ki = 455 µM) for this unique inhibitor.124 
H
N
1
4.1. Hydroxamate derivatives
4.1.1. Primary and secondary benzhydroxamic acids
Almost fifty years ago, Schonbaum et al.117 described the first hydroxamate inhibitors of the 
alternate oxidase pathway of plant mitochondria. These primary benzhydroxamic acids (2, 4, 
810, 12, 13, 1823) specifically and reversibly inhibited the cyanide-insensitive respiratory 
pathway in munk bean (Phaseolus aureus) and skunk cabbage (Symplocarpus foetidus). m-Chloro 
and m-iodobenzhydroxamic acids (9 and 10, respectively) were the most potent inhibitors tested 
with IC50 values < 50 µM (Figure 2).117 One year later, in 1973, Evans and Brown reported that 
m-CLAM (9) inhibited the cyanide-insensitive respiration of bloodstream forms of T. brucei in 
vitro.55,150 Opperdoes and co-workers showed that SHAM (2) was another powerful inhibitor of 
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the α-glycerophosphate oxidase (GPO) system of T. brucei.151 Specifically, this system oxidizes 
glycerol-3-phosphate (G3P) using an electron transport system in the inner mitochondrial 
membrane consisting of G3P dehydrogenase, ubiquinone, and the trypanosome alternative 
oxidase (TAO). SHAM was shown to inhibit GPO non-competitively (Ki = 21 µM).124
NOTE: for consistency, we will refer to inhibition of GPO, as measured by the inhibition of 
oxygen uptake, for the earlier studies on AOX inhibitors (before 1996) and to inhibition of TAO 
for later studies using the recombinant rTAO enzyme.57 
Only primary and secondary aromatic hydroxamates are active (Figures 23), whereas aliphatic 
and alpha-amino acid hydroxamates did not inhibit the T. brucei GPO.123,124 m-Substituted 
benzhydroxamates with a chlorine (9) or iodine (10) atom at C2 were equipotent inhibitors and 
twice as active as SHAM. o-Substituted benzhydroxamic acids with hydrogen bond (HB) 
donating groups such as OH (2) or NH2 (3) gave the most potent inhibitors. Among the SHAM 
analogues, 3- and 5-substituted derivatives (2024) provided no improvement in inhibition 
compared to 2. According to this study, no correlation exists between the inhibition of GPO and 
either the acidity (pKa) or the affinity for iron of the hydroxamate derivatives.124 
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N
H
O
HO
R
Cpd R T. brucei Ki (M)
2 (SHAM) OH 21
3 NH2 33
4 H 152
5 Me 169
6 F 300
7 Cl 567
R
N
H
O
HO
Cpd R T. brucei Ki (M)
8 F N/A
9 (m-CLAM) Cl 10
10 I 11
11 Br 20
12 Me 23
13 NO2 329
N
H
O
HO
29: Ki = 132 M
(T. brucei)
OH
OH
OH
N
H
O
HO
R1
R2
Cpd R1 R2 T. brucei Ki (M)
14 NMe2 13.2
15 Cl Cl 52
16 NO2 62
17 OH 1043
18 Cl N/A
19 CO2H N/A
O
N
H
HO
O
N
H
HO
N
O
N
H
HO
IC50 (M)
Cpd Skunk cabbage Mung bean
2 260 60
4 400 90
8 240 60
9 160 30
10 50 20
12 350 90
13 300 60
18 320 90
19 1070 210
25 220 N/A
26 810 240
27 1300 180
28 890 160
O
N
H
HO
25 26
27 28
Cpd R T. brucei Ki (M)
2 H 21
20 OH 19
21 Me 40
N
H
O
HO
OH
R
N
H
O
HO
OH
R
Cpd R T. brucei Ki (M)
22 OH 38
23 Br 55
24 Me 77
Figure 2. Ki and IC50 values for the inhibition of the cyanide-insensitive terminal oxidase pathway 
(inhibition of oxygen uptake) of T. brucei, skunk cabbage, and mung bean by primary 
benzhydroxamic acids.55,117,124,150
Secondary benzhydroxamic acids showed decreased potency compared with the primary 
hydroxamates (Figure 3, compare 9 vs 3034).124 Even though the inhibitory effect seemed to 
depend on the size of the N-alkyl substituent (n-hexyl > Me > c-hexyl > Ph) – and be limited by 
the bulkiness of R – no clear trend was detected with regards to the potency of inhibition for these 
secondary hydroxamates.
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N
O
HO Cl
R
N
O
HO
34: Ki = 1865 M
Cpd R Ki (M)
9 H 10
30 Bn 47
31 n-hexyl 185
32 c-hexyl 1340
33 Me 1198
Figure 3. Ki values for the inhibition of the AOX pathway (inhibition of oxygen uptake) of T. 
brucei by secondary benzhydroxamic acids.124 
4.1.2. N-hydroxy heterocycles
Clarkson et al also evaluated a series of heterocyclic compounds in which the hydroxamate 
moiety was part of the ring system (Figure 4). The activity of 1,4-dihydroxy-2(1H)-quinolinone 
36 and its 3-bromo analogue 37 was comparable to that of the most active benzhydroxamates 
shown in Figures 2 and 3.123,124 Parent compound 35, lacking the 4-hydroxy group, was a 
significantly less potent inhibitor of T. brucei AOX. 
Aurachins are quinoline antibiotics isolated from myxobacteria.152 Aurachin C analogues with an 
n-decyl (38a) or n-octyl (38b) chains strongly inhibit the cyanide-insensitive NADH oxidation of 
higher plant mitochondria.153 Similarly to 35, the aurachin D analogue 38c, lacking the 4-OH 
group, was much less effective than 38a and 38b indicating that the N-OH group is essential for 
potent AOX inhibition.154 However, both types of aurachins are not specific AOX inhibitors as 
they also act strongly at the Qi site of the cytochrome bc1 complex.153 Compound 38a also inhibits 
T. vivax AOX in the micromolar range (Figure 4).155
Other N-hydroxyheterocyclic compounds such as 4-hydroxy-2H-benzo[b][1,4]thiazin-3(4H)-
ones (41–45), 2-dodecyl-1-hydroxyquinolin-4(1H)-one (38), 1-hydroxy-3-methylquinazoline-
2,4(1H,3H)-dione (39), and 1,3-dihydroxy-1,3-dihydro-2H-benzo[d]imidazol-2-one (40) were 
less active than the 1,4-dihydroxy-2(1H)-quinolinones. Of note was the lack of activity of the 1,1-
dioxo derivative 46 compared with 41.
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N O
OH
S
N O
OH
OO
46: Ki > 2000 M, inactive
N
N
O
OH
OH
40: Ki = 1650
M
N
N
O
O
OH
39: Ki = 1500 M
R1
N
R2
O
R1
T. vivax
Cpd R1 R2 IC50 (M)
38a (Aurachin C1-10) n-decyl OH 28
38b (Aurachin C1-8) n-octyl OH
38c (Aurachin D1-10) n-decyl H
S
N O
OH
R1
R3
Cpd R1 R2 R3 Ki (M)
41 H 527
42 Me 152
43 CF3 837
44 CH2CO2Me 768
45 Me >2000
R2
Cpd R1 R2 Ki (M)
35 H 172-238
36 OH 27
37 OH Br 10-83
R2
Figure 4. Ki values for the inhibition of T. brucei alternative oxidase pathway (inhibition of 
oxygen uptake) by heterocyclic N-hydroxy compounds. IC50 value for the inhibition of T. vivax 
AOX.123,124,155
4.1.3. Alkyloxybenzhydroxamic acids and related compounds
In these series of alkyloxybenzhydroxamic acids, the inhibitory activity against GPO depends on 
the length and the position (para > ortho) of the alkyloxy substitutent (Figure 5). Increasing the 
number of methylene units in the alkyl chain results in an increase of GPO inhibition even though 
this effect is not linear (47–58). The best activity was observed with the n-tetradecyl chain in para 
position (57). Indeed, this compound displayed the highest inhibitory activity (Ki = 0.43 µM) 
among all the reported hydroxamate series.123 These data confirmed that lipophilic substituents 
enhance GPO inhibition and that substitution in para to the hydroxamate group is preferred 
(compare 50/60, 54/61, and 56/62). However, long chain para-alkyloxybenzhydroxamates have 
limited aqueous solubility. Replacement of the ether with an amide linkage (63, 64) was 
detrimental to the activity while providing no significant improvement in solubility.123 A 
summary of the SAR of benzhydroxamic acid derivatives is presented in Figure 6.
Grady et al. showed that the mechanism of inhibition of these long chain hydroxamates is 
reversible and that they are not acting as detergents. Compound 56 was shown to kill 100% of T. 
b. brucei bloodstream forms in vitro, at a concentration of 50–100 µM in the presence of 10 mM 
glycerol. Thus, 56 was 10–20 times more active than SHAM in killing trypanosomes in vitro. 
However, the limited solubility of 56 or 57 prevented in vivo activity.123
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N
H
O
HO
OR
Cpd R
47 Me
48 Et
49 n-Pr
50 n-Bu
51 n-Pent
52 n-hexyl
53 n-heptyl
54 n-octyl
55 n-decyl
56 n-dodecyl
57 n-tetradecyl
58 n-hexadecyl
59 Bn
N
H
O
HO OR
O
N
H
HO
H
N
O
63: Ki = 50 M
O
N
H
HO
N
H
O
64: Ki = 103 M
Ki IC90 (M)
18.6 191
13.9 120
8.3 70
13.9 136
19.3 201
9.4 77
5.8 55
7.0 59
3.6 36
1.1 10
0.43 2.8
1.0 19
200
Cpd R
60 n-Bu
61 n-octyl
62 n-dodecyl
Ki (M)
71
18.2
9.4
Figure 5. Ki and IC90 values for the inhibition of T. brucei alternative oxidase pathway (inhibition 
of oxygen uptake) by alkyloxybenzhydroxamic acids and related compounds.123
O
N
H
HO
X alkyl
R
Hydroxamate conjugated to Ar ring - Lipophilic substuents increases inhibition (para > ortho)
- n-C14H29 is best
- the effect of increasing the length of alkyl chain is not linear
- limited solubility for long alkyl chains
X = O > NHCO
Inhibition rate does not correlate with
hydroxamate acidity or affinity for iron
Diiron
centre
of AOX
Fe
Fe
Outside of AOX
Figure 6. SAR of benzhydroxamic acid derivatives
4.2. Other iron chelators: tropolones, 8-hydroxyquinolines, and pyridine derivatives
In addition to hydroxamates, several classes of iron-chelating agents – tropolone (65–69), 8-
hydroxyquinoline (70, 71), and pyridine derivatives (72–76) – were assayed as GPO inhibitors 
(Figure 7).124 Tropolone (67, Ki = 122 µM) was 2.5 times more active than 4,5-benzotropolone 
(68). However, the most potent inhibitor of this series was the 3-bromo benzotropolone derivative 
65 which was 6- and 15-times more potent than 67 and 68, respectively. In contrast, 8-
hydroxyquinoline derivatives (70, 71) were poor inhibitors and the (5-hydroxy-2-
(hydroxymethyl)-4H-pyran-4-one 73 and pyridines 74–76 were all inactive. Among these iron 
chelators, lipophilic aromatic substituents enhanced inhibition (compare 67/68/65, 70/71) 
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whereas hydrophilic anionic substituents (sulfonate 72 vs 71) had the opposite effect. These 
findings, which were in line with the SAR of benzhydroxamates (Figure 6), supported the view 
that iron binding per se plays at best a minor role in GPO inhibition and that other lipophilic 
interactions with the TAO binding site are essential.
O
OH
O
OH
O
OH
Br
O
OH
67: Ki = 122 M66: Ki = 110 M 68: Ki = 303 M65: Ki = 18 M
N
OH
71: Ki = 780 M
N
OH
70: Ki = 413 M
Br
Br
N
OH
SO3H
O
HO
O
OH
Inactive compounds
N
O
HO
O
OH
N
OH
OH N
OH
SH
O
OH
69 (Purpurogallin)
OHHO
HO
72 73
74 75 76
Figure 7. Ki values for the inhibition of T. brucei alternative oxidase pathway (inhibition of 
oxygen uptake) by iron chelators: tropolone (65–69), 8-hydroxyquinoline (70–72), and pyridine 
derivatives (74–76).124
4.3. Mono, di- and trihydroxybenzoic acid, benzaldehyde, and benzoate derivatives
4.3.1. Benzoic acid derivatives
Sidow et al. showed that neither benzoic acid nor 4-hydroxybenzoic acid (90) inhibit the 
alternative oxidase pathway in mung bean mitochondria.156 The same result was observed in T. 
brucei.125 In contrast, 2,4-dihydroxybenzoic acid 80 or other 2-substituted-4-hydroxybenzoic 
acids (78, 81–83) are > 10-times more potent inhibitors against rTAO, indicating that the ortho 
substituent at C-2 (e.g. OH, F, Me) is essential for potent inhibition by 4-hydroxybenzoic acid 
derivatives (Figure 8).13
Gallic acid (79), a known iron chelator that lacks the 2-OH group, is a micromolar inhibitor of T. 
brucei GPO.125 In contrast, this compound does not inhibit the alternative pathway in mung bean 
mitochondria at a concentration up to 1 mM.156 Removal of the 4-OH (84–88) or protection with 
a methoxy group (91) yields inactive compounds indicating that the 4-OH group is important for 
Page 26 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27
potent inhibition of benzoic acid derivatives. Substitution of the 4-OH group with a geranyl tail 
enhanced the inhibition potency against recombinant TAO enzyme by approximately 50- to 100-
fold (compare 80/92, 81/93, 82/94, and 83/95) yielding single digit micromolar inhibitors.126 
Amazingly, the introduction of one more isoprenyl unit in the farnesyl derivative 96 led to a 
further improvement in inhibition by 3-orders of magnitude (IC50 = 3.1 nM).126 The SAR of 
benzoic acid derivatives is summarized in Figure 9.
HO
O
OH
OH
HO
O
OH
R1
R2
Cpd R1 R2 IC50 (M)
80 OH 116
81 OH Me 143
82 Me 112
83 F 115
R1
R2
Cpd R1 R2 Ki IC90 (M)
77 H 730
78 OH 32
79 H OH 218
HO
O OR1
R2
R3
Cpd R1 R2 R3 Ki (M)
84 H >1000
85 H OH >1000
86 H OH Br >1000
87 Me OMe >1000
88 H OH >1000
HO
O
OR2
R1
R3
Cpd R1 R2 R3 Ki (M)
89 OMe H OMe >1000
90 H >1000
91 OMe Me H >1000
R1O
O OH
O
Cpd R1 R2 IC50 (M)
92 OH 2.1
93 OH Me 2.4
94 Me 0.92
95 F 1.1
OR2
HO
O R1
O
OH
R2
Cpd R1 R2 IC50 (M)
96 H 0.0031
97 Et Ac >5
Figure 8. Ki and IC90 values for the inhibition of T. brucei alternative oxidase pathway (inhibition 
of oxygen uptake) by benzoic acid derivatives.125 IC50 values for the inhibition of purified 
rTAO.13,126
O
HO
O R3
R1
H not allowed
OH > Me, F
H or isoprenyl chain (farnesyl >> geranyl)
Me not allowed
R2
Me if R1 = OH
O is essential
Inactive if the 2-OH and 4-OH are absent
Inactive if the 2-OH and 4-OH are absent
Diiron
centre
of AOX
Fe
Fe
Outside of AOX
Figure 9. SAR of benzoic acid derivatives
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4.3.2. Benzoate and benzamide derivatives
The methyl and ethyl hydroxybenzoates (98, 100–102, 106, 108–109, 116–129) display 
comparable SAR to that of hydroxybenzoic acids 77–97, suggesting a similar mode of binding to 
TAO, with the carboxylate group in close proximity to the diiron catalytic center (Figures 8 and 
10).13,126 Esters of 2,5-dihydroxybenzoic acid (106, 107) had no inhibitory effect even though the 
orientation of the hydroxyl groups better mimics that of ubiquinol.125 Substitution of the 4-OH 
group with a lipophilic geranyl (123-126) or C14 alkyl chain (127) yielded low micromolar 
inhibitors.126 In contrast, the benzoate derivatives with a larger alkyl substituent (R1) are expected 
to bind AOX in a different way, with the ester alkyl chain pointing outward from the active site 
(Figure 11B). In this series, the Ki decreases as the length of R1 increases (Figures 10: 102–115 
and Figure 11A: 130–144). Submicromolar inhibitors were obtained when the alkyl chain is ≥ C6 
(141–144). The most potent inhibitor, dodecyl 3,4-dihydroxybenzoate 144 (IC90 = 0.88 µM), was 
almost 12-fold stronger inhibitor than its benzhydroxamic acid counterpart 56 (IC90 = 10 
µM).123,125 In the 3,4-dihydroxybenzoate series, methylation of the 3-OH (133, 137) or 4-OH 
(138) was detrimental to inhibition. 
The 2-hydroxybenzamide compounds 151 and 152 were designed as analogues of the benzoic 
acid 150 with a solubility-enhancing carbohydrate moiety. These compounds inhibited rTAO 
competitively with micromolar IC50 values (Figure 11). They also inhibited parasite respiration 
and parasite growth (EC50 =16.5, 33.6, and 33.1 µM for 150, 151, and 152, respectively) in a 
dose-dependent manner.157 
3,4-Dihydroxybenzoates have significant trypanocidal activity in mice when combined with 
glycerol (15 mg/kg p.o.). For instance, the i.p. administration of 143 (800 mg/kg) combined with 
glycerol reduced the parasitemia; no cures were obtained with this dose but no overt toxicity was 
observed either, and a higher dose might have been possible. The combination of glycerol and n-
propyl gallate (110) suppressed the parasitemia to a lesser extent and it was also more toxic to the 
mice.125 
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OH
R1O
O
Cpd R1 Ki (M) IC90 (M)
98 Me >1000
99 n-Pr 2800
R1O
O
Cpd R1 R2 R3 Ki (M) IC90 (M)
100 Me 120
101 Me Me >1000
102 Me Br 500
103 n-Pr 462
104 n-octyl 426
105 n-dodecyl 194
OR3
OR3 R1O
O OH
OH
R2
OH
OH
O
R1O
T. brucei Munk bean
Cpd R1 R2 R3 Ki IC90 Ki (M)
108 Me OH 451 5-6
109 Et OH 4-5
110 n-Pr OH 6.3 3
111 n-Bu OH 2-3
112 n-Bu OMe 450
113 n-Bu H OH 370
114 n-octyl OH 1.6 0.3-0.4
115 n-dodecyl OH 3.3
Cpd R1 Ki (M)
106 Me >1000
107 n-Pr >900
R2
R3
Cpd R1 R2 IC50 (M)
122 OH nd
123 OH Ac >5
124 Me 1.7
125 Me Ac >5
126 F >5
MeO
O
OR2
Cpd Isomer R1 R2 IC50 (M)
127 4-subst. Me 2.3
128 3- Me >5
129 4- Et Me >5
3
4
R1O
O (CH2)14-BrR2
EtO
R2
R3
R4
Munk bean
Cpd R1 R2 R3 R4 Ki (M)
116 H >1000
117 OH >1000
118 OH >1000
119 OH 60
120 OH OH 12-15
121 OH OH >1000
O R1
OO R1 OH
Figure 10. Ki and IC90 values for the inhibition of the alternative oxidase pathway (inhibition of 
oxygen uptake) in T. brucei13,125,126 and munk bean156 by benzoate derivatives. IC50 values for the 
inhibition of purified rTAO.
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Cpd R1 R2 R3 Ki (M) IC90 (M)
130 H 730
131 Me 68
120 Et 54
132 n-Pr 3.0
133 n-Pr Me >1000
134 i-Pr 4.9
135 sec-Bu 10.6
136 n-Bu 22
137 n-Bu Me >1000
138 n-Bu Me >80
139 i-Bu 3.2
140 i-pentyl 10.4
141 n-hexyl 0.53 5.6
142 n-octyl 0.55 4.3
143 n-decyl 0.37 3.3
144 n-dodecyl 0.88
Cpd R1 IC90 (M)
145 Et 368
146 n-Bu 9.4
147 n-hexyl 11
148 n-octyl 4.5
149 n-decyl 0.62
R1
O
O
H
N
O
OR2
OR2
OR2O2NO
R1
Cpd R1 R2 IC50 (M)
150 (ACB41) OH 5
151 (ACD15) Ac 10
152 (ACD16) H 50
OH
A
B
O
X
RO
R1
R1, R2: Me, OH > F
Alkyl or isoprenyl chain (geranyl)
Inhibition increases with chain length
R2
O, NH > CH2
O: stability to serum hydrolases depends on R1/R2
NH: more soluble, more stable to hydrolases, lower LD50
Diiron
centre
of AOX
Fe
Fe
Outside of AOX
R3
R
R = H, OH
MeO is not favorable
Carbonyl conjugated to Ar ring
Figure 11. (A) Ki and IC90 values for the inhibition of T. brucei alternative oxidase pathway 
(inhibition of oxygen uptake) by 3,4-dihydroxybenzoate, 3,4-dihydroxybenzamide, and 2,4-
dihydroxybenzoic acid derivatives. IC50 values for the inhibition of purified rTAO. (B) SAR and 
binding orientation of benzoate and benzamide derivatives with large R1 alkyl substituents. 
The replacement of the benzoate linkage with a benzamide group (145–149) produced inhibitors 
that were more soluble and more stable to serum hydrolases in vivo than the 3,4-
dihydroxybenzoate analogues, and several were more active (146, 149) against the target enzyme 
than the corresponding ester (136 and 143).158 In fact, the n-butyl-3,4-dihydroxybenzamide 146 
was found to be curative in T. b. brucei-infected mice (450 mg/kg by i.p. dosage) when co-
administrated with glycerol (15 g/kg p.o. in 3 doses at hourly intervals). The in vivo toxicity of 
the benzamide 145–149 and benzoate compounds (136, 141–143) decreased when the alkyl chain 
contained more than 6 methylene units. Of note, the amides had slightly lower LD50 values than 
Page 30 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
31
the ester counterparts.158 Importantly, 3,4-dihydroxy aromatic compounds (153) are inactive if the 
carboxyl (e.g. acid) group is not linked directly to the phenyl ring (Figure 12).
R
HO
HO
O
OH
NH2
O
OH
O
OH
OH
N
H
NH2
O
OH
R (T. brucei: Ki > 1000 M)
153
HO
R1
R2
Munk bean
Cpd R1 R2 Ki (M)
Phenol H >1000
Resorcinol OH >1000
Catechol OH 350
Pyrrogallol OH OH 30-40
Figure 12. Ki values for the inhibition of the alternative oxidase pathway (inhibition of oxygen 
uptake) by miscellaneous phenol derivatives125,156
A series of highly potent TAO inhibitors based on the 4-hydroxybenzoate scaffold were described 
recently (Figure 13). These compounds inhibited the physiologically relevant form of TAO, i.e. 
that lacking the N-terminal 25 amino acid mitochondrial targeting sequence (ΔMTS-TAO), in the 
low nanomolar range.13 As observed with the previous benzoate series, a correlation between 
inhibitory activity and methylene chain length was observed, the longest alkyl chains giving the 
best inhibitors: C14 (159–161) > C16 (163, 164) > C12 (157) >> C10 (156) > C6 (155) > C4 
(154). Geranyl substituent at R3 (165) gave an inhibitor equipotent126 to the tetradecane chain 
analogues 158–161. 4-Hydroxybenzoates dimers with a C14 (168) or C16 (169) methylene linker 
were equipotent to their monomer counterparts (158 and 163, respectively) showing that the 
second pharmacophore unit (i.e. 2,4-dihydroxybenzoate group) does not add to the inhibition 
potency with such long alkyl linkers. In contrast, dimers with shorter linkers (C10, C12) were 2- 
to 20-fold more inhibitory than their monomer counterparts (157/167 and 156/166, 
respectively).13 Interestingly, the 4-hydroxybenzoate derivatives displayed in Figure 13 are more 
potent TAO inhibitors than the corresponding 4-alkoxy benzoic acid (92–95) and benzoate 
analogues (122–127, 129) shown in Figures 8 and 10. 
Most of these 4-hydroxybenzoate inhibitors 154–165 were active in the micromolar range against 
wild-type and drug-resistant strains of T. brucei in vitro (EC50 < 25 µM) whereas the dimers (166–
170) were less effective (EC50 > 25 µM).13
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O
O
R3
R1
HO
Cpd R1 R2 R3 IC50 (M)
154 OH (CH2)4Br 0.45
155 OH (CH2)6Br 0.24
156 OH (CH2)10OCHO 0.150
157 OH (CH2)12Br 0.0174
158 OH (CH2)14Br 0.0108
159 OH Me (CH2)14Br 0.007
160 Me (CH2)14Br 0.007
161 Me (CH2)14OCHO 0.0011
162 F (CH2)14Br 0.030
163 OH (CH2)16Br 0.0124
164 OH (CH2)16OCHO 0.0144
165 OH 0.0091
R2
O
O (CH2)n
R
HO
O
O
OH
R
Cpd R n IC50 (M)
166 OH 10 0.0069
167 OH 12 0.007
168 OH 14 0.0157
169 OH 16 0.0123
170 Me 14 0.013
OAc
Figure 13. IC50 values for the inhibition of purified rTAO by 4-hydroxybenzoate derivatives.13
4.3.3. Benzaldehyde and benzophenone derivatives
Benzaldehyde derivatives were first investigated as analogues of benzoic and benzhydroxamic 
acids (Figure 14). In these aldehyde (171–179) and ketone series (181–185), two adjacent 
hydroxyl groups are necessary to inhibit the AOX pathway: R1/R2 (171) > R1/R2/R3 (172) > R2/R3 
(173). Other orientations of hydroxyl groups (176–178) or methylation of one (174, 178) or both 
(175) OH groups abolished activity.125 Aldehydes 171–173 were found to be much better 
inhibitors (3- to 30-fold) than their respective benzoic acid counterparts 77, 78, and 85.124,125 
The natural isoprenoid antibiotic ascofuranone (188) is one of the most potent (subnanomolar) 
inhibitors of TAO reported to date (Figure 14).113 The alkoxy analogues of AF substituted in para 
(186) and ortho position (187) with a geranyl tail are less inhibitory than AF by 3 orders of 
magnitude.159 In contrast, the more lipophilic 2-hydroxy-4-alkyloxy derivative 180 is a nanomolar 
inhibitor (IC50 = 73 nM).126 These data, which agree with the SAR reported for benzoate and 
benzoic acid derivatives, further demonstrate that the effects of the substituent (tail) in para of 
the carbonyl group are mainly due to non-specific lipophilic interactions. 
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R4
O
OH
R2 R1
Cpd R1 R2 R3 R4 Ki (M) IC90 (M)
181 OH 16
182 OH OH Et 77
183 OH OH 128
184 OH Me >1000
185 OH NHMe >1000
R3O
R1
OR2
R3
Cpd R1 R2 R3 Ki (M)
171 OH 15-29
172 OH OH 88
173 OH 190
174 OH Me >1000
175 OMe Me >1000
Cpd R1 R2 R3 Ki (M) IC50 (M)
176 OH >1000
177 OH OH >1000
178 OH OH >1000
179 OH OMe >1000
180 O(CH2)14Br OH 0.073
O
R1
R3
R2
OR1
Cl
OR2
Cpd R1 R2 IC50 (M)
186 H 1.0
187 0.251
O OH
Cl
OH
R
O
188 (Ascofuranone, AF) 0.13
189 H (Colletochlorin B, CCB) 0.2
O
O
Cpd R IC50 (nM)
Figure 14. Ki and IC90 values for the inhibition of T. brucei alternative oxidase pathway 
(inhibition of oxygen uptake) by benzaldehyde and keto derivatives. IC50 values for the inhibition 
of purified rTAO.59,113,125,126,159
4.4. 3-chloro-4-hydroxybenzonitrile derivatives
After the groups of Kita, investigating the pharmacophore of ascofuranone (188), reported that 
the electron withdrawing cyano group was a useful alternative to its formyl group,59 West et al. 
investigated the SAR of 3-chloro-4-hydroxybenzonitrile analogues.159,160 With the aim of 
reducing the lipophilicity of the tail region of inhibitor 200, and thereby improve its 
physicochemical properties including the predicted CNS Multiparameter Optimization (MPO)161 
score, they introduced different polar groups (amide, ether) in the lipophilic tail (Figure 15).160 A 
large decrease in inhibition potency compared to the n-octyl analogue 190 was observed with 
amide (191–196) and ether groups (197–199), showing that even minor increases in polarity in 
this part of the lipophilic tail are not tolerated. The introduction of polarity at the terminal part of 
the chain (195, 196, 198, 199) seemed to be somewhat better tolerated but these compounds were 
inactive in vitro against T. b. brucei,160 probably because of poor cellular uptake. This shows that 
alternative strategies are needed in order to improve the physicochemical properties of these TAO 
inhibitors.
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With regards to the alkyl chain analogues, TAO inhibition and T. brucei growth inhibition 
correlated with chain length and clogP;160 compounds 200–207 showed a distinct decrease in 
potency for each carbon reduction, in line with previous SAR reports.59 In particular, a notable 
decrease in TAO inhibition was observed for alkyl chains ≤ C3. 
NC
Cl
OH
R
H
N
O
N
H
O
N
H
O
H
N
O
N
O
O
O
O
NC
Cl
OR2
R1
Cpd R1 R2 IC50 (M)
200 n-octyl 0.0013
201 n-octyl Me 31.6
202 n-heptyl 0.0032
203 n-hexyl 0.0063
204 n-pentyl 0.0158
205 n-butyl 0.02
206 n-propyl 0.079
207 Me 0.631
Cpd R IC50 (M)
190 0.1
191 3.2
192 >31.6
193 25.1
194 25.1
195 7.9
196 4.0
197 15.8
198 2.5
199 6.3
N
H
O
Figure 15. 3-chloro-4-hydroxybenzonitrile derivatives: influence of tail hydrophilicity and 
methylene chain length on rTAO inhibition.159,160
4.5. Ubiquinone analogues
AOX enzymes catalyze the oxidation of ubiquinol to ubiquinone with concomitant four-electron 
reduction of oxygen to water (Figure 16).8,162 Hence, different ubiquinone-like compounds 
derived from 1,4-naphthoquinone (208, 209) and 4,7-dioxobenzothiazol (210) were assayed as 
AOX inhibitors. Maesaquinone (208) was found to inhibit the AOX pathway in plant 
mitochondria isolated from Arum maculatum spadices, with IC50 <0.3 µM; it also inhibited the 
cytochrome pathway, albeit at approximately one order of magnitude higher concentrations.163
Ubiquinone analogues 209 and 210 also inhibited the AOX pathway of T. brucei with much lower 
Ki values (20- to 600-times) than SHAM (2). A more polar analogue of 209 lacking the lipophilic 
side-chain, 2-hydroxynaphthoquinone (211), had little effect (20% inhibition) at a 50 µM 
concentration (Figure 16).164 
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Ferulenol (212) is a prenylated 4-hydroxycoumarin that was first isolated from the plant Ferula 
communis165 and shows potent antimycobacterial activity.166 This compound, which is a potent 
inhibitor of the L-malate:quinone oxidoreductase (PfMQO) of the malaria parasite Plasmodium 
falciparum,167 also inhibits TAO (Balogun and Kita, unpublished data). 
O
O
OH
209: Ki = 1 M
S
N
O
O
OH
210: Ki = 0.030 M
OH
MeO
MeO
OH
H
10
Ubiquinol
O
O
OH
MeO
OMe
OMeOMe
213 (Stigmatellin)
O
MeO
MeO
O
H
10
Ubiquinone
O
O
OH
211
O
OH
O
212 (Ferulenol)
AOX
1/2 O2 H2O
O
O
HO
OH
208 (Maesaquinone)
Figure 16. Ki values for the inhibition of T. brucei alternative oxidase pathway (inhibition of 
oxygen uptake) by ubiquinol analogues.164
4.6. Natural products: isoprenoid antibiotics 
4.6.1. Ascofuranone derivatives
Ascofuranone (AF, 188) was the first natural isoprenoid antibiotic reported to inhibit TAO in the 
subnanomolar range.113 It was later found to be active in vivo in mouse models of T. brucei and 
T. vivax infections.74,130,137 Because of its remarkable inhibitory potency and its promising curative 
activity, SAR studies were performed59,159,160 and a pharmacophore was defined (see section 
5.2.1.).59 Analogues were synthesized to try to circumvent the unwanted features of ascofuranone 
(e.g. electron rich aromatic ring, aldehyde group, phenol, and lipophilic side chain) that may 
contribute to the rapid blood clearance, low oral bioavailability, and potential toxicity of this 
compound (Figures 17–18). 
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A methyl group at C-6 is important but not essential for inhibition as shown by the 3-fold loss of 
activity of 214 vs 188 (Figure 17). Replacement of the formyl group (R1) with an acetyl group 
(215, 217, 218) gave similar inhibitory activity as AF whereas an oxime group (216) reduced the 
potency by 2 orders of magnitude. Other electron withdrawing group preferred at R1 were NO2 
(223) > CN (224) >> CO2Me (252).59 A carbonyl linkage between the phenyl ring and the alkyl 
tail is favored (219, 221) in comparison with a methylene linker (220, 222).10 
OH
R1
R2
Cl
OH
O
O
Cmpd R1 R2 IC50 (nM)
188 (AF) CHO Me 0.13
214 CHO 0.45
215 COMe Me 2.5
216 (C=NOH) Me 28
OH
OH
Cl
H3C
O
R
Cmpd R IC50 (nM)
217 CH2OCOtBu 0.70
218 Me 0.15
OH
X
OH
Cl
H3C
R2
Cmpd R1 R2 X IC50 (nM)
219 (K2-9) H C=O 250
220 (K4-9) H CH2 4000
221 Cl Me C=O 200
222 Cl Et CH2 10000
223 NO2 Et CH2 0.45
224 CN CH2OCOtBu CH2 6.0
225 Ac CH2OCOtBu CH2 100
R1
Figure 17. SAR of ascofuranone (AF): modification of the aromatic head. IC50 values for the 
inhibition of purified rTAO.10,59 
The low nanomolar IC50 values of alkyl chain derivatives of AF (232, 243, 244) and alkyl 
analogues lacking the furanone ring (228–231) show that the geranyl chain and the furanone ring 
are not essential for potent inhibition of TAO. In these series, the optimum chain length for potent 
inhibition is between 9 and 12 carbon atoms (229–231). The analogue with a chain shorter than 
C3 (226) was 1000-fold less inhibitory than AF indicating that hydrophobic interaction is required 
for inhibition. Bulky groups at the end of the isoprenyl or alkyl tail have little influence on TAO 
inhibiton (217, 235, 242) suggesting that these groups are not interacting with the enzyme, 
possibly because they are located at the surface or outside TAO. Taking into account these SAR 
results, compound 247 was synthesized as the most potent TAO inhibitor reported to date (IC50 = 
0.06 nM).59
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OHO
H3C
Cl
OH
Cpd R IC50 (nM)
226 Me 100
227 n-Pr 3.8
228 n-pentyl 0.7
229 n-heptyl 0.38
230 n-octyl 0.38
231 n-decyl 0.45
232 1.0
R
OHO
H3C
Cl
R3
R1
O
O
O
O
O
O
O
OHO
H3C
Cl
OH
R
O
O
Cpd R IC50 (nM)
233 CH2OH 1.2
234 (AF27790OH) CH(OH)CH3 0.48
235 CH2OCOtBu 0.4
236 CH2CH2OAc 1.4
188 (AF) 0.13
O
O
O
O
O
O
Cpd R1 R2 R3 IC50 (nM)
237 CO2H OH 40
238 CH2OH OH 6.0
239 (CH2)4CO2H OH 4.2
240 OH 0.30
241
OH 0.32
242
243 OH 0.50
244 Me OH 0.30
245 OMe 4.0
246 Et 30% inhibition
at 50 M
O
O
R2R2
O
O
O
O
OHO
H3C
Cl
OH
247: IC50 = 0.06 nM
Figure 18. SAR of ascofuranone: modification of the aliphatic tail. IC50 values for the inhibition 
of purified rTAO.10,59
4.6.2. Colletochlorin B derivatives
Colletochlorin B (CCB, 189), a fungal metabolite isolated from Colletotrichum nicotianae that 
contains a diprenyl side chain,168 is a close analogue of AF (188) that strongly inhibits TAO. 
However, unlike AF and AF2779OH (234), CCB is toxic to mice.10 
Due to their structural similarities, AF and CCB display comparable SAR (Figure 19). For 
instance, electron withdrawing groups at R1 (248–252) are preferred (CHO ≈ CN ≈ Ac > CO2Me 
>> C=NOH, CH3). For the nitrile analogue 249, however, a drop in efficacy was observed against 
T. brucei even though enzyme inhibitory potency was retained. A methyl group at R2 contributes 
significantly to the inhibition of TAO (189, 249, 258) albeit to a lesser extent than that of a 
chlorine atom at R3 (258, 259).159 
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An interesting analogue is the bicyclic 1,2-isoxazole 253, a synthetic intermediate to access the 
nitrile analogue 249 that displays high inhibitory potency against TAO (IC50 = 5 nM) and T. b. 
brucei (EC50 = 0.1 µM). 
 
R1
OH
R2
Cl
OH
O OH
R2 OH
O OH
R2
R3
OAc
OH
Cl
OAc
262: IC50 = 2.0 ×103 nM
Cl
OH
ON
253: IC50 = 5 nMCpd R1 R2 IC50 (nM) IC50 (nM)
189 (CCB) CHO Me 4.0 0.2
248 CHO 100 0.23
249 CN Me 4.0
250 CN 25
251 (C=NOH) 794
252 CO2Me Me 45
Cpd R2 IC50 (nM) IC50 (nM)
254 Me 3.2 ×103 0.5
255 OH 3.2 ×103
256 H 4.0 ×103
257 H 38
Cpd R2 R3 IC50 (nM)
258 Me Cl 320
259 H Cl 0.5 ×103
260 Me 4.0 ×103
261 H 3.2 ×103
Figure 19. SAR of colletochlorin B (CCB). IC50 values for the inhibition of purified rTAO 
reported by West et al159,160 and Saimoto et al59 (left and right IC50 values, respectively).
4.6.3. Ilicicolin derivatives
The effect of ilicicolin antibiotics, isolated from a Verticillum sp fungus,169 was tested against 
AOX from T. vivax (Figure 20).155 The kinetic analysis of the inhibition of T. vivax by these 
antibiotics showed that compounds 263–265 act as (apparently) non-competitive inhibitors, 
similarly to AF113 and SHAM.157 Ilicicolin D (263) was the best (low nanomolar) inhibitor 
whereas the acetylated analogue 264 was nearly 30 times less potent. Removal of one double 
bond in the tail part of the molecule (265) led to a 3-fold drop in inhibition relative to 263. 
Removal of the chlorine atom at C3 of the phenyl ring led to a 14-fold fall in inhibition potency 
(265/266). 
Comparing the IC50 value of the farnesyl derivative 267 (150 nM) with that of its geranyl analogue 
254 (Figure 19, 3.2 µM) indicates that an extra isoprenyl unit in the chain seems to be favorable 
to AOX inhibition (keeping aside the difference in trypanosome species being used for the test: 
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T. vivax and T. brucei for 267 and 254, respectively). This effect is in line with that observed for 
the benzoic acid series (see section 4.3.1). It is also congruent with the higher resemblance of the 
farnesyl group with the isoprenyl chain of the natural substrate ubiquinol.
OH
OH
Cpd Name R1 IC50 (nM)
263 Ilicicolin D H 15
(Ascochlorin)
264 Ilicicolin F Ac 430
O OH
OH
O
267 (Ilicicolin B)
IC50 = 180 nM
R1Cl
O
OH
OH
Cpd Name R1 IC50 (nM)
265 Ilicicolin C Cl 46
266 LL-Z1272 H 650
O
R1
O
Figure 20. SAR of ilicicolin derivatives. IC50 value for the inhibition of T. vivax AOX.
5.   STRUCTURE-AIDED INHIBITOR DESIGN
5.1. TAO structure
Although TAO was first identified and described as a promising target for the design of new and 
safe anti-Trypanosoma drug a long time ago,120,17 its structure was determined only recently,10 
and it is the first and the only structure of any alternative oxidase to date. The long gap between 
its discovery and structure solution was attributable to problems such as low purification yield 
and protein instability.144 Commendably, these problems were eventually solved by Kita’s 
group,45 allowing them to crystallize TAO61 and determine its structure.10 The structure of TAO 
was determined by X-ray crystallography in ligand-free/apo form and in complex with its 
inhibitors at a resolution of up to 2.3 Å.10 Judging from the quality indicators resolution, Rwork and 
Rfree and Ramachandran plots (Figure 21), the 3-D structure solution is of acceptable quality and 
accuracy for Structure-Aided Drug Design (SADD) (Table 2). Interestingly, known inhibitors of 
TAO (SHAM and AF) had earlier been discovered,119,113 making SADD targeting TAO a lot 
easier. Guided by the TAO structure, efforts are currently ongoing to modify AF and SHAM 
structures in order to obtain more potent inhibitors with better drug-like properties.13,59,62,159,160 
Before the crystal structure of TAO was determined, investigations into its molecular architecture 
used a combination of biochemical data (enzymatic activity, electrophoresis, site-directed 
mutagenesis, electron paramagnetic resonance (EPR), inductively coupled plasma-mass 
spectrometry, (ICP-MS)) and bioinformatics by homology modelling, and the combined studies 
led to the prediction that TAO was a non-heme di-iron membrane protein and included a helix 
bundle core.14,16,45 
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Figure 21. Ramachandran Plot statistics for TAO-CCB (PDB ID: 3W54). PROCHECK was used 
to prepare and assess the quality of the TAO structure data and for its suitability for use in SADD. 
93.3% of the residues were in most favored regions, 6.7% in additional allowed regions, and none 
in generously allowed and disallowed regions (0.0%). The statistics reveals that the structure is 
above the acceptable accuracy cut-off of 90%, hence, may be useful for SADD.
Table 2. Data collection and refinement statistics for TAO (3W54) in comparison with the 
acceptable limits for SADD. The deposited structure qualifies to be used for SADD
Determinants of quality
 
TAO Acceptable limit for SADD
Resolution (Å) 2.3 2.5
Rwork 18.5 25
Rfree 22.7 28
Ramachandran (%)  93.3 90
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These predicted structural elements were confirmed by the crystal structure, which additionally 
revealed that, unlike as earlier model, TAO is functionally a dimer and a monotopic membrane 
protein (i.e. membrane-attached but lacking a membrane-spanning domain) (Figure 22A).10 The 
enzyme is a homodimer and the monomers lack any βsheet but is made up of six long antiparallel 
helices (αL1 – αL6) and four short helices (αS1 – αS4) (Figures 22A & B). The dimer interphase 
accounts for about 35% of the total dimer accessible surface and is formed by highly conserved 
amino acid residues, which are located in helices αL2, αL3, and αL4 of each monomer of TAO. 
In addition to the long helices, the long portion of the N-terminus (Pro31 to Arg62), forming αS1- 
αS3 and the adjoining loops, extends to form part of the dimer interphase (Figure 22C). Helix αS4 
(Val242-Tyr246) is not directly involved in the interphase formation; it partly interacts with the 
long arm within the same chain and contributes to stabilizing the long arm for inter-chain 
interaction (Figure 22C). The amino acids that forms αL1, αL4, the C-terminal of αL2, and N-
terminal of αL5 are largely hydrophobic. As such, these helices formed a broad surface, which 
was proposed to be the part of each monomer that is used for anchorage to the inner mitochondrial 
membrane,10 as earlier predicted by Anderson and Norlund.170 
Importantly, the structure revealed that TAO lacks a transmembrane helix; Shiba et al10 calculated 
that only about 8.4 Å of the membrane-interacting surface, corresponding to a helix radius, is 
‘inserted’ into the membrane (Figure 22A). This confirmed that TAO is peripheral monotopic 
protein using conserved positively charged amino acids (Arg106, Arg180, Arg203, and Arg207) 
at the membrane interphase for interaction with negatively charged phospholipid head groups of 
the mitochondrial inner membrane.10,1 This monotopic (interaction with only one leaflet of the 
membrane lipid bilayer) nature of TAO is similar to that of prostaglandin H2 synthase (PGHS-
2),171,172 except that while TAO is barely inserted beyond the phospholipid head of the membrane 
leaflet, a longer portion of PGHS-2 is inserted into the entire leaflet, making PGHS-2 an integral 
monotopic protein.172 
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Figure 22. X-ray crystal structure of TAO. Long α-helices are labeled αL, while short helices are 
labelled αS. Diiron and hydroxo atoms are shown as spheres. (A) Cartoon representation of the 
dimeric structure viewed roughly parallel to the helix axes. Helices are shown as ribbons. Chain 
A is rainbow-colored while chain B is colored cyan. Each monomer consists of six long helices 
(αL1 – αL6 in chain A, αL1’ – αL6’ in chain B) and four short helices (αS1 – αS4 in chain A and 
αS1’ – αS4’ in chain B). Except for the N-terminal arm, each monomer is shaped as a compact 
cylinder. Horizontal beige bars depict the two leaflets of the inner mitochondrial membrane, 
where residues of αL1, αL4 and portions of αL2 and αL5 form the membrane-anchoring base. (B) 
Membrane side of the monomers. Length of the long helices could be visualized to appreciate the 
broad surface formed by αL1 and αL4 for membrane interaction. (C) Dimer formation. Two 
monomer chains A and B intimately associated to form the functional dimer of TAO. Chain A is 
represented as cartoon while chain B as surface model. The monomers ‘hug’ each other with their 
long N-terminal arm where the short helices are located, additionally, helices αL2, αL3, and αL4 
participate in the dimerization. (D) A zoom-in on the diiron center. The diiron center is created 
by six amino acid residues, Glu123, Glu162, His165, Glu213, Glu266, and His269. Two iron ions 
(Fe1 and Fe2 shown as green spheres) are ligated by the glutamate residues via coordinate bonds 
(shown as solid lines). Iron ion Fe1 directly coordinates the hydroxo group in the diiron center. 
The histidine residues participate in the stabilization of the diiron center by forming hydrogen 
bonds with the glutamate residues. 
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One of the explanations for the earlier findings that AOXs were inhibited by SHAM, a metal 
chelator, led to their classification as metaloenzymes.117 A few years later, the presence of Fe was 
reported, based on spectroscopic analyses,45,1,173 bearing out the predictions of the presence of Fe 
based on the diiron binding motif of AOXs.173,174 Indeed, the structure of TAO revealed the 
presence of two ferric ions positioned about 3.3 Å and bridged together by one hydroxo group, 
which together with the coordinating amino acids (four glutamate residues; Glu123, Glu162, 
Glu213, Glu266 and two histidine residues; His165 and His269) form the diiron center in the 
active site (Figure 22D) of each monomer.10 
Remarkably, Shiba et al10 also successfully determined the structure of TAO in complex with AF 
derivative AF27790H. The inhibitor was bound in a cavity that is located near the membrane 
surface between αL1 and αL4, and coordinated by 16 highly conserved amino acids amongst 
which are Glu123 and Glu213, two of the glutamate residues that bind the Fe3+ cofactors and help 
form the catalytic diiron centre (Figure 23A). This implies that the inhibitor was bound close to 
the catalytic center, revealing the mechanism of inhibition. In fact, binding of the inhibitor 
affected the position of Fe1, causing its displacement towards His165 by approximately 1.2 Å 
(Figure 23A). It was proposed that AF27790H,  a structural analogue of ubiquinone,1 was bound 
at the substrate binding site of the enzyme. The TAO-AF27790H structure (PDB ID: 3AAV) has 
been used for modeling, to infer the possible binding patterns of new series of 4-hydroxybenzoate 
and 4-alkoxybenzoate derivatives to TAO (Figure 23B).13,126 The model supported the 
enzymological inhibitory kinetics of the derivatives, which characterized a number of them as 
competitive inhibitors of TAO.13 Due to the availability of the crystal structure of TAO in the 
ligand-free and inhibitor-bound forms, there are renewed efforts towards utilizing the structure 
data for rational design of new inhibitors with improved potency and drug-like properties above 
AF and SHAM.13,18,62,126,159,160 
Although TAO is the only alternative oxidase whose structure has been experimentally 
elucidated, this has allowed the comparative modelling of other AOX in the context of explaining 
differences in catalytic efficiency and inhibitor sensitivity. This has recently been expertly 
reviewed by May et al.7 They proposed that, although the active site and the structure of the 
hydrophobic cavity is highly conserved, the major differences in Vmax and, for instance, sensitivity 
to AF, can be attributed to differences in the hydrophobic tunnel giving access to the central 
cavity.
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Figure 23. Structure of TAO-inhibitor complex. (A) Complex structure of TAO (cyan sticks) 
bound with ascofuranone derivative AF2779-OH (yellow stick); the structure is superposed with 
the diiron center of the uninhibited form (green sticks). The diiron and hydroxo of the inhibited 
form are brown and blue spheres, respectively. While the diiron and hydroxo of the uninhibited 
form are green and yellow spheres, respectively. The inhibitor is bound in the active site of TAO 
close to the diiron center. Binding of the inhibitor caused a displacement of the Fe1, the Fe2 is 
not affected. (B) Model structure of SHAM derivative 322. 
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5.2. Ascofuranone as template for inhibitor design
5.2.1. Ascofuranone pharmacophore
The discovery by Minagawa et al113 of the inhibitory action of ascofuranone (AF) against the 
respiration and growth of bloodstream forms of T. b. brucei opened the path to a new class of 
highly potent AOX inhibitors. Ascofuranone is a prenylated phenol antibiotic, which was first 
isolated by Ando and co-workers175 from an organism that was initially described as the 
phytopathogenic fungus Ascochyta visiae but now re-identified as Acremonium sclerotigenum.176 
The structure of ascofuranone comprises a chlorinated orsenilaldehyde and a furanone group in 
the extremities, connected through a prenyl linker (Figure 24A). 
The exhaustive SAR studies of the ascofuranone scaffold by Kita and co-workers led to the 
construction of the AF pharmacophore for binding to the AOX substrate binding site (Figure 
24B).59 The main characteristics were summarized by Saimoto et al59 as follows: 1) the hydrogen-
bonding capacity of the 1-formyl and 6-OH groups is responsible for potent inhibition of AOX. 
However, their role depends on the structure of the lipophilic tail; 2) the furanone ring is not 
essential for strong inhibition; 3) One isoprene group in proximity to the aromatic ring is 
recognized by the enzyme; 4) The 2-methyl and/or 3-chloro groups contribute to the enzyme-
bound conformation of the molecule. 
O
OH
Diiron
catalytic
centre
of AOX
Fe1
Fe2
Outside of AOX
Cl
H
O
OH> OMe>> H
O
O
HB donor HB acceptor Isoprene is favored
Furanone ring not essential
OH
OH
O
Cl
O
O
Aromatic ring
linker
Furanone
Headgroup Tail
A B
Figure 24. (A) Structural features of ascofuranone (188). (B) Ascofuranone pharmacophore: 
functional interaction between AF and AOX.59 Dash-lines represent H-bonds with amino acids of 
the inhibitor binding site.
Despite the potent activity of AF against trypanosomes in vitro113 and in vivo,74,130,137 the 
development of AF-like inhibitors has been hampered by the less-than-optimum drug-like 
properties of this scaffold (e.g. high lipophilicity, low water solubility) due in part to the presence 
of an aldehyde group and a lipophilic side-chain. Moreover, the complex chemical structure of 
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AF, which requires long multistep synthetic strategies resulting in high synthesis cost, has limited 
the access to synthetic analogues. The fact that the 3D-structure of TAO was unknown until 
201310 has further hindered strategies for the rational design of AOX inhibitors. Altogether, this 
can probably explain the apparent lack of interest from the scientific community in developing 
AF derivatives during almost 30 years (from the mid-1980’s). In the next section, we illustrate 
these synthetic difficulties with an overview of the reported synthesis approaches to the 
ascofuranone scaffold. 
5.2.2. Synthetic strategies towards ascofuranone derivatives
Over the years, several routes towards the synthesis of AF and its analogues have been reported 
in the literature. Indeed, most of the efforts were devoted to the modification of i) the substituents 
in the phenolic head group, aiming either to explore the structural-activity relationship or to 
improve chemical coupling efficiency,159,160 and ii) the linker structure and length.59 The first 
synthetic efforts (1970–2000) employed mainly two main strategies, based on an arene alkylation 
route (Scheme 1) or on non-aromatic alkylation/aromatization strategies (Scheme 2).
5.2.2.1. Arene alkylation strategies
In the 1970s–80s, the typical synthesis route comprised the introduction of the vinyl group via 
aromatic SN2 substitution (Scheme 1a), usually leading to very low yields of the product. The 
prenyl chain grafting step was later improved by protecting the phenolic substrate introduced in 
a late stage of the synthesis (Scheme 1b).177 
a) Ima-ye (1973),178 Mori (1984),179 Chen (1984),180 Ohta (1988)181
+
X R
OH
X
OH
R
OH
X
OH
R
R
H+ or
OH-
(7-57%)
b) Saimoto (1986)177
Br R
+
Cl
OSEM
OSEM
CO2Me
OSEM
Cl
OSEM
CO2Me
R
Cu HMPA
(91%)
Scheme 1. Different synthetic strategies employing early stage aromatic head group 
functionalization. SEM: 2-(Trimethylsilyl)ethoxymethyl.
5.2.2.2. Non-aromatic alkylation/aromatization strategies
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The first robust and general method of synthesis of AF was developed by Mori179,182 and featured 
tert-butyllithium-based alkylation of 1,5-dimethoxy-3-methyl-1,4-cyclohexadiene 268 with an 
halogenated geranyl tail as key step (Scheme 2). This method proved successful for the synthesis 
of AF (188) and illicicolin derivatives (263, 266), but harsh conditions were needed and overall 
yields did not exceed 15%.179,182 
Cl R
+
OMe
OMe
OMe
OMe
R
tBuLi
HMPA
(67%)
268
Scheme 2. Synthetic strategy employing early stage aromatic head group functionalization: Mori 
(1983, 1984)179,182
In the particular case of AF (188), precursor 268 was connected to 269 via SN2 displacement to 
yield 270 (Scheme 3).179 Another 5 synthetic steps lead to (±)-AF which was obtained in very 
poor overall yield (0.03%). The problems encountered in this route (i.e. high number of steps, 
poor yields, especially for the acetal deprotection and 268 grafting), were tackled in later years 
by pre-producing the suitable head group, and by developing alternatives in the 
protection/deprotection approaches for the phenolic OH groups.
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34% OHC OH
NaBH4
100%
OHC O O77% O O
OHO
OH
73%
OH
O
ORO
O
R = THP, 53%
R = H, 96%
R = Ac, 90%
p-TsOH
AcOH
Ac2O
XO
X = OAc, 80%
X = OH, 93%
269: X= Br, 90%
K2CO3
O
O
OTMSTMSO
MeO
MeO O
O
O
MeO
OMe
tBuLi, 33%
NCS
31%
O
O
O
O
O
Cl
Cl
O
O
O
HO
OH
Cl
DBU
50%
1) EtMgBr
2) CH(OEt)3
3) H3O+
O
HO
OH
Cl
CHO
188
270
271
272
21%
268
O
1) n-BuLi
2) pTsCl
3) LiBr
SeO2
Scheme 3. Synthesis of (±)-ascofuranone employing early stage head group functionalization179
In the mid 1980’s, Saimoto and co-wokers177 overcame the limitations observed in Mori’s 
pathway and developed a more convergent synthesis of Colletochlorin B and D. In this approach, 
the fully protected aromatic head group was prepared separately and introduced at a later stage of 
the synthesis (Schemes 4 and 5). First, condensation of either dimethyl malonate with 3-penten-
2-one 274 or of methyl acetoacetate with methyl crotonate 273 gave the 4-oxocyclohex-2-ene 
adduct 275 in good yields. Dehydrobromination, followed by chlorination and alcohol protection 
either with Me2SO4 or SEM-Cl, led to the protected resorcinol-based analogues 279 and 280, 
respectively. Nevertheless, this step could lead to undesired by-products.183
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Me
Me
O
+
CO2Me
CO2Me
O
OH
CO2Me
Me
CO2Me
O
MeCO2Me
Me
+
O
OHMe
Br CO2Me
Br
OH
OHMe
CO2Me
Br
OH
OHMe
CO2Me
BrCl
OMe
OMeMe
CO2Me
BrCl
MeONa NaH
AcOHBr2
SO2Cl2
274
275
273
276
277
278
88%
71%
42%
46%
67%
97%
279
OSEM
OSEMMe
CO2Me
BrCl
280
97%
Scheme 4. Synthesis of the fully-protected aromatic head group (279, 280) of colletochlorin and 
ascofuranone from aliphatic starting materials.177
In the following step (Scheme 5), the aromatic head precursors 279 and 280 were coupled 
orthogonally with either geranyl or prenyl bromides via an organocuprate intermediate to give 
281 and 282 in good yields.177 The early introduction of the electrophilic carbonyl in the synthetic 
pathway, did not seem to restrict posterior nucleophilic addition of the isoprenoid linker. Serious 
problems were encountered to deprotect the OH groups following the conditions of Guthrie et 
al183 (i.e. only one SEM group was removed), but removal of the SEM protecting groups was 
achieved successfully using TBAF in HMPA177 at 70 ºC for 2.5 h to give CCB (189) in 70% yield. 
In parallel, the deprotection of OMe groups was successfully achieved in harsh conditions by 
treatment with either EtSNa in HMPA, or EtSMgBr in DMF, leading to moderate yields of CCB 
(189) and CCD (285), respectively (Scheme 5). 
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OR
ORMe
CO2Me
Cl R'
OR
ORMe
CHO
Cl R'
OH
OHMe
CHO
Cl R'
1) n-BuLi
2) CuC CC(OMe)Me2
3) geranyl bromide or
BrCH2CH=CMe2
281: R = Me, 70%
282: R = SEM, 91%
1) LiAlH4
2) PyHClCrO3
1) EtSNa-HMPA, R' = CH2CH=CMe2
2) EtSMgBr-DMF, R '= H
283: R = Me, 97%
284: R = SEM, 97%
285 (CCD): R' = H (53%)
189 (CCB): R' = CH2CH=CMe2 (64%)
OR
ORMe
CO2Me
Cl Br
TBAF in HMPA
OH
OHMe
CHO
Cl
189 (70%)
279: R = Me
280: R = SEM
Scheme 5. Colletochlorin B and D synthesis177
Mori reported the first synthesis of the natural enantiomers of ascochlorin and ascofuranone;184  
(-)-ascochlorin was obtained in 22 steps (0.035% overall yield) starting from (R)-(+)-pulegone 
whereas (-)-ascofuranone was synthesized in 17 steps from geraniol (0.073% overall yield). 
Improved enantioselective synthesis of AF was achieved 10 years later,185 by replacing the acetate 
protecting group located in the 2,5-dihydrofuran heterocycle (287) with a bulkier pivaloyl ester 
(Scheme 6). More importantly, chirality transfer was shown to be quantitative, indicating that 
cyclization of 286 to 287 was more rapid than isomerization of the allene intermediate. The 
chirality was induced via asymmetric reduction of the starting alkynones with (S)-Alpine 
borane.185,186
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THPO
OH
O
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1) (S)-Alpine Borane
2) tBuCOCl, DMAP
H
ee 84%
OH
OH
CHO
Me
Cl
286
287(S)-( )-188
Scheme 6. Asymmetric synthesis of (S)-(-)-ascofuranone (188)
In 2000, an original approach to the synthesis of (-)-ascochlorin (263) was reported by Dudley et 
al.187 In this route, an elegant cyclobutenone-based benzannulation is introduced as tool for 
assembling the aromatic core (Scheme 7). On the downside, this strategy requires a specifically 
designed alkynyl ether and long-time photoirradiation (>40 h) (Scheme 7). 
OH
Cl
CH3
CHO
HO
O
OH
Cl
CH3
CHO
R'O
R
OR'R
H O
ClH3C
+
H3C
H
O
Cl
R O
R'O Cl
CH3
CH3
H
R'O
R
O
Cl
4 electron
electrocyclic
cleavage
[2+2]
cycloaddition
4 electron
electrocyclic
cleavage
6 electron
electrocyclic closure
(and tautomerization)
263
Scheme 7. Mechanistic course of the benzannulation key step: Dudley (2000)187
In summary, none of the synthetic approaches to AF derivatives described in the period 1970–
2000 offer both generality and efficiency; yields tend to be low and harsh conditions are required. 
Since SAR studies have shown that structural modifications of the furanone tail have only minor 
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influence on AOX activity, recent synthetic efforts have explored more accessible routes to 
structurally-simpler AF analogues.
5.2.2.3 Recent strategies 
In the recent period (2010-2018), improved synthetic approaches based on the direct coupling of 
the functionalized tail group to the aromatic head (Scheme 8) or other routes allowing the 
structural diversification of the scaffold were reported (Scheme 9). These new synthetic routes 
are of particular interest because they dramatically decrease the number of synthetic steps and 
allow the introduction of diverse substituents, a key parameter when performing SAR studies. 
A. Direct coupling 
In 2010, a new synthetic approach to (±) ascofuranone in just 7 steps starting from geranyl acetate 
was reported by Haga et al.188 The chemical pathway involved the preparation of the brominated 
prenyl side-chain precursor bearing a furanone ring (288), and subsequent direct coupling with 
the non-protected aromatic moiety 289 under basic conditions, in the presence or absence of CaCl2 
(Scheme 8). The presence of CaCl2, which acts as Lewis acid coordinating both molecules, 
resulted in higher yields (35–44%) and the absence of by-products. This was the first ever route 
featuring direct coupling of 288 with the functionalized aromatic ring 289.
OH
OH
Cl
O
CaCl2
OH
OH
Cl
O
 O
O
KOH, MeOH
35%
O
O
Br
+
288 188289
Scheme 8. Direct coupling in the absence of protecting groups: Haga (2010)188
B. Diversifiable routes
The focus in the last two years has shifted to the synthesis of diversifiable routes as it provides 
access to a wide number of natural product derivatives reducing the synthetic cost of production 
(Scheme 9).
R
OH
X
Y
OH
O
O 7 steps
R= Me
R=
Scheme 9. Diversifiable route to polysubstituted phenolic compounds: Grabovyi (2016),189 West 
(2017, 2018)159,160 
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Grabovyi et al189 discovered an alternative towards the total synthesis of polysubstituted phenolic 
natural products featuring terpenoid side chains (Scheme 10). This pathway, in which the phenolic 
head group is introduced early in the synthesis, is advantageous because it uses accessible 
protecting groups (e.g. MOM, Boc, and TBS) that are easily cleaved using HCl, ZnBr and 
tetrabutylammonium fluoride (TBAF), respectively, and it allows the gram scale synthesis of the 
products in high overall yields (>50%). The main drawback is the harsh conditions requested 
during the course of the divergent routes.
O
O 2) TBSCl
O
OTBS
1) LiHMDS, TsCl
2) TBAF
1) EtMgBr
HC(OEt)3
2) aq. HCl
89% 71%
80%
LL-Z1272
MeO OMgOMe
O
Ilicicolinic
acid40%
1) 20 mol% L-proline
Hantzsch ester
OH
OH
Cl
HO
O
OH
OH
Cl
O
OH
OH
Cl
O
Scheme 10. Total synthesis scheme of natural products LL-Z1272α and ilicicolinic acid
Recently, West et al159,160 studied the key step in the synthesis of AF-like compounds consisting 
in the installation of the prenyl chain in the aromatic ring. The reaction between alkyl or geranyl 
bromides via lithiation and subsequent electrophilic aromatic substitution (Scheme 11), led to 290 
in excellent yields. However, once again, removal of the protecting groups was challenging and 
afforded a poor yield (15%) of the product 291. 
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O OMOM
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OR1
OR1
O OH
OH
290
15%
R1 = H
R1 = MOM
48%
93%
NaH, MOMCl
n-BuLi,
geranyl bromide Deprotection
291
Scheme 11. Alkylation of protected resorcinol-like analogue
Deprotection of the phenolic groups in the course of AF synthesis has been a major problem over 
the years. Saimoto’s attempts177 to reproduce Chen’s procedure180 for the deprotection of Me-
ethers (i.e. trimethylsilyl iodide in CHCl3/pyridine for 4 days) was not successful. Hence, an 
alternative using P2I4 under neutral conditions was proposed to cleave the 1-alkoxymethyl aryl 
ether under mild conditions (Scheme 12).190 
P2I4
CH2Cl2, 0 ºC
45 min,
70%
OSEM
Cl
CO2Me
OSEM
Br
OH
Cl
CO2Me
OH
Br
Scheme 12. Example of SEM ether deprotection using P2I4190
However, this protocol is also under debate as Fürstner et al191 and Marsico and co-workers,192 in 
further attempts, found complications (e.g. decomposition of the starting material) in the 
deprotection of SEM ethers using P2I4. In both cases, these problems were avoided using TBAF 
in hexamethylphosphoramide (HMPA).193 Thus, the availability of deprotection methods for the 
phenolic OH groups remains a critical issue when developing alternative routes to AF-like 
compounds.
Another route developed by West et al,159 based on non-aromatic alkylation/aromatization 
strategy, allowed facile diversification of the phenolic moiety through lithiation chemistry. This 
improved structural diversity and overall yields (Scheme 13).
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Scheme 13. Diversifiable synthesis159
5.3. Mitochondrial targeting strategy using lipophilic cations
Notwithstanding all the recent methodological progress in the synthesis of AF derivatives, it is 
clear that the development of ascofuranone-like inhibitors remains somewhat limited, from a 
medicinal chemistry point of view, by the synthetic challenges associated with the modification 
of this scaffold. 
Over the last several years, our group has developed an innovative strategy to boost the anti-
parasite activity of structurally simple AOX inhibitors derived from the 2,4-dihydroxybenzoic 
acid scaffold (80). The localization of AOX to the inner surface (matrix side) of the inner 
membrane of mitochondria1,162 has inspired us to use mitochondrion-targeting strategies for AOX 
inhibitors. Recent reports by our group13,28,62,194,195 and others196,197 have shown that coupling 
antiparasitic agents with lipophilic cations is an effective chemotherapeutic approach to deliver 
compounds specifically to the mitochondrion of protozoan parasites. In particular, the 
triphenylphosphonium (TPP) cation, which holds a charge that is delocalized over a large and 
hydrophobic surface area, can cross lipid bilayers by non-carrier mediated transport 
electrophoretically driven by the plasma and mitochondrial transmembrane potentials (Figure 
25).198 Other cations such as quinolinium salts are also effective mitochondrion-targeting 
groups.62,199
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P Linker TAO inhibitor
Bloodstream
p m
Plasma membrane
BSF trypanosome
Cytoplasm
Accumulation:
~ 100-500 fold
P Linker TAO inhibitorAccumulation: ~ 5-10 fold
Figure 25. Schematic representation of uptake and accumulation of mitochondria-targeted 
triphenylphosphonium (TPP) TAO-inhibitor conjugates within BSF trypanosomes. ΔΨp, plasma 
membrane potential; ΔΨm, mitochondrial membrane potential.
The SAR of the different series of AOX inhibitors reported to date has shown that a certain level 
of lipophilicity, and a minimum length, is required in the tail region of the molecule to exhibit 
potent inhibition (see section 4). In particular, compounds holding a C12 or C14 chain are more 
inhibitory than shorter analogues. Hence, a series of 4-alkoxybenzoate derivatives (292–305) 
conjugated to a TPP or 1-quinolinium lipophilic cation via a methylene linker were synthesized 
(Figure 26).13 We found, consistent with previous reports and other series of benzhydroxamates 
and 4-hydroxybenzoates (Figures 6 and 13, respectively), that a linker length of 14 carbons was 
preferred (297, 299, 301–305) while shorter or longer linkers were detrimental to TAO 
inhibition.13,62 For compounds 301–305, the introduction of the mitochondrion-targeting LC in 
the structure of inhibitors 159, 160, and 162 hardly affected their inhibitory potency against rTAO, 
indicating that the LC does not interfere with binding to TAO when a tetradecane linker is used.
As expected, mitochondrial targeting increased the potency of the compounds against wild type 
and drug-resistant strains of T. brucei and T. congolense by up to 3 orders of magnitude (EC50 
values from 0.6 to 210 nM), reflecting a similar improvement in mitochondrial accumulation. 
Selectivity of the LC-conjugates over human cells was also greatly improved vs non-cationic 
inhibitors.13 In general, the TPP cation was a more efficient mitochondrion-targeting moiety than 
the 1-quinolinium salt. Within this 4-hydroxybenzoate series, compounds 302 and 303, featuring 
OH and Me groups in ortho to the ester bond were metabolically stable in mouse serum and 
human microsomal fractions. In vivo, both compounds reduced the parasite load of mice infected 
with T. b. rhodesiense by 95% 24 h post-treatment by intraperitoneal administration (4×10 
mg/kg), without co-administration of glycerol.13
The 4-hydroxybenzaldehyde–LC conjugates 306 and 307 inhibited TAO (IC50 = 0.22 and 1.23 
µM) and T. brucei growth with EC50 values in the same concentration range (0.133 and 1.75 µM, 
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respectively).13 SAR studies showed that the methyl ester analogues 309 and 310 were 10-times 
more potent whereas the free carboxylic acid derivative (317–321) were less effective (> 5 µM). 
Within this series, the 2-hydroxy-6-methyl carboxylate derivative 322 was the most potent (low 
nanomolar) inhibitor of the enzyme and of T. brucei growth.126 
HO
O
O (CH2)n
R1
R2
LC+
rTAO T. brucei
Cpd R1 R2 n LC+ IC50 (M) EC50 (M)
292 OH 8 TPP >50 0.073
293 OH 9 TPP >50 0.0059
294 OH 10 TPP >50 0.0013
295 OH 12 TPP >5 0.0012
296 OH 12 Quin >5 0.33
297 OH 14 TPP 1.46 0.0015
298 OH 16 TPP >5 0.009
299 OH 14 Quin 1.36 0.10
300 OH 16 Quin >5 0.14
301 F 14 TPP 0.030 0.0006
302 OH Me 14 TPP 0.088 0.0016
303 OH Me 14 Quin 0.104 0.032
304 Me 14 TPP 0.081 0.0024
305 Me 14 Quin 0.030 0.21
3
4
O R1
O (CH2)n LC+
rTAO T. brucei
Cpd R1 R2 R3 n Subst. LC+ IC50 (M) EC50 (M)
306 OH 14 4- TPP 0.22 0.133
307 OH 14 4- Quin 1.23 1.75
308 OH OMe 10 4- TPP >5 0.002
309 OH OMe 14 4- TPP 0.015 0.018
310 OH OMe 14 3- TPP 0.012 0.028
311 F OMe 14 4- TPP 0.74 0.05
312 F OMe 14 4- Quin >5 2.4
313 Me OMe 14 4- TPP >5 0.018
314 Me OMe 14 4- Quin >5 0.16
315 OH Me OEt 14 4- TPP 0.25 0.05
316 OH Me OEt 14 4- Quin >5 0.29
317 OH OH 10 4- TPP >5 0.73
318 OH OH 14 4- TPP >5 0.086
319 F OH 14 4- TPP >5 0.037
320 Me OH 14 4- TPP >5 0.19
321 Me OH 14 4- Quin >5 10.6
322 OH Me OH 14 4- TPP 0.0042 0.013
R2
R3
Figure 26. IC50 values for inhibition of purified ΔMTS-TAO and EC50 values against T. b. brucei 
(WT) by 4-hydroxybenzoate–lipocation (LC) conjugates (292–305), 4-alkoxybenzaldehyde–LC 
conjugates (306, 307), and (3)4-alkoxybenzoate–LC conjugates (308–322). The IC50 of SHAM 
(2) is 5.93 µM in this assay.13,62,126 TPP: triphenylphosphonium. Quin: 1-quinolinium.
6. OUTLOOK AND CLINICAL PERSPECTIVE 
The first mention of alternative oxidases can be traced to the 1920s35 and are now known to have 
important functions in many different organisms. In plants, the principal functions of AOX appear 
to be related to growth under adverse or stress conditions including drought84,200- a topic of intense 
interest in relation to agriculture and food security. The role of AOX was also investigated in 
many fungi of agricultural or medical importance and it was similarly found to be important in 
their stress response, and to contribute to pathogenicity and virulence. Yet, the enzyme is not 
believed to be essential to most fungi and is not considered a target for drugs against fungal 
infection, at least not as monotherapy. 
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The main pharmacological focus has been on the trypanosome alternative oxidase, which is a 
well-validated target. Several major challenges slowed progress for a considerable time: (1) the 
early inhibitors including SHAM were of low potency and required co-administration of large 
quantities of glycerol in vivo; (2) the ab initio synthesis of derivatives of the best available early 
inhibitor, ascofuranone, was chemically poorly accessible; (3) the enzyme proved very difficult 
to produce and purify in large enough yield to obtain structural information through crystallization 
and X-ray diffraction; (4) improved potency of the enzyme inhibitors (Ki values) did not translate 
in similar potencies against the parasites in vitro or in vivo. However, over the last few years, each 
of these hurdles has been successfully taken. 
(1) SHAM remained the standard TAO inhibitor for a long time, despite its low efficacy and the 
need for huge doses in vivo, in combination with even larger amounts of glycerol. The discovery 
of ascofuranone for the first time allowed the cure of infected animals with moderate doses and 
no glycerol co-administration. This breakthrough demonstrated that further improvements in 
trypanocidal potency and/or pharmacokinetics could deliver a genuine preclinical candidate.
(2) Multiple important improvements have been made to the synthetic routes to structurally-
simpler ascofuranone analogues, allowing the construction of chemical library for SAR studies 
and the optimization of lead compounds. 
(3) The production of TAO in bacteria suffered from the presence of prokaryotic cytochromes 
performing essentially the same reaction. The construction of an E. coli strain lacking the first 
step in heme synthesis, but able to grow when complemented by an intermediate metabolite (5-
aminolevulinic acid) or the expression of TAO, literally an alternative oxidase, was a major step 
in solving this problem, as was the painstaking optimization of solubilization detergents and 
purification protocols. The outlook has further improved with the shift to ΔMTS-TAO, which, 
lacking the functionally redundant N-terminal sequence, is better soluble and displays greater 
yield, stability, and specific activity.
(4) Optimization of inhibitors, particularly when driven by structure-aided design, necessarily 
focus on the primary aim of improving interaction with the target, measured as binding affinity 
or inhibition constants. However, the optimized inhibitors do not necessarily display improved 
anti-parasite activity as there is no presumption of a correlation between inhibition of a target and 
the ability to reach that intracellular target.201,202  In the case of TAO, it is only the concentration 
of the inhibitor locally, inside the T. brucei mitochondrion that determines the antiparasite 
efficacy. This requires efficient uptake of the drug by the parasite into the cytosol and its further 
translocation into the mitochondrion. Both the plasma membrane and the inner mitochondrial 
membrane are inside-negative, with a strong membrane potential providing a driving force for the 
accumulation of cations that can actively or passively cross the lipid bilayer. This, essentially, 
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forms the basis of the effectiveness of the cationic trypanocides including pentamidine,203 
diminazene,204 furamidine205 and isometamidium.65 Since all classical TAO inhibitors including 
SHAM and ascofuranone are uncharged at physiological pH, uptake was neither efficient nor 
concentrative. This problem was overcome by the coupling of lipophilic cations via long (C12 or 
C14) linkers to the inhibitors, allowing the intra-mitochondrial concentration to increase by 
several hundred-fold for the same extracellular concentration or dose. This has reversed the 
paradigm by creating molecules with a much lower anti-parasite EC50 than enzyme inhibition 
IC50.13,62 
Altogether, the potency observed with the TAO inhibitor–LC conjugates shows that 
mitochondrial targeting with lipophilic cations is a promising strategy to boost the trypanocidal 
efficacy of AOX inhibitors, and that it can work in vivo. At least some of these molecules were 
stable in serum and when challenged by Phase I or Phase II metabolism in pharmacokinetic tests. 
In preliminary in vivo studies with these inhibitors T. b. rhodesiense parasitemia was reduced 95% 
with 4 daily doses of 10 mg/kg.13 However, an improvement of the drug-like properties of these 
conjugates, and a much more thorough evaluation of in vivo behavior will be required if they are 
to be used as anti-parasite drugs. The initial argument that TAO is a druggable and essential 
trypanosome enzyme without a mammalian counterpart is still valid and the breakthroughs of the 
last few years give every reason for optimism.
ACKNOWLEDGEMENTS
Funding from the Spanish Ministerio de Economia y Competitividad (grant SAF2015-66690-R) 
and the Japan Society for the promotion of Science (JSPS grant-17F17420) is gratefully 
acknowledged.
Page 59 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60
REFERENCES
1. Moore AL, Shiba T, Young L, Harada S, Kita K, Ito K. Unraveling the Heater: New 
Insights into the Structure of the Alternative Oxidase. Annu Rev Plant Biol. 
2013;64(1):637-663.
2. Moore AL, Albury MS. Further insights into the structure of the alternative oxidase: from 
plants to parasites. Biochem Soc Trans. 2008;36(Pt 5):1022-1026.
3. McDonald AE, Vanlerberghe GC. Origins, evolutionary history, and taxonomic 
distribution of alternative oxidase and plastoquinol terminal oxidase. Comp Biochem, 
Physiol Part D, Genomics & proteomics. 2006;1(3):357-364.
4. Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiases. Lancet. 
2003;362(9394):1469-1480.
5. Williams BAP, Elliot C, Burri L, et al. A Broad Distribution of the Alternative Oxidase 
in Microsporidian Parasites. PLoS Pathogens. 2010;6(2):e1000761.
6. Roberts CW, Roberts F, Henriquez FL, et al. Evidence for mitochondrial-derived 
alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: A potential 
anti-microbial agent target. Int J Parasitol. 2004;34(3):297-308.
7. May B, Young L, Moore AL. Structural insights into the alternative oxidases: Are all 
oxidases made equal? Biochem Soc Trans. 2017;45(3):731-740.
8. Young L, Shiba T, Harada S, Kita K, Albury MS, Moore AL. The alternative oxidases: 
Simple oxidoreductase proteins with complex functions. Biochem Soc Trans. 
2013;41(5):1305-1311.
9. Yan L, Li M, Cao Y, et al. The alternative oxidase of Candida albicans causes reduced 
fluconazole susceptibility. J Antimicrob Chemother. 2009;64(4):764-773.
10. Shiba T, Kido Y, Sakamoto K, et al. Structure of the trypanosome cyanide-insensitive 
alternative oxidase. Proc Nat Acad Sci 2013;110(12):4580-4585.
11. Vanlerberghe GC. Alternative Oxidase: A Mitochondrial Respiratory Pathway to 
Maintain Metabolic and Signaling Homeostasis during Abiotic and Biotic Stress in 
Plants. Int J Mol Sci. 2013;14(4):6805-6847.
12. Giordani F, Morrison LJ, Rowan T, De Koning HP, Barrett MP. The animal 
trypanosomiases and their chemotherapy - a review. Parasitol Int. 2016;143(14):1862-
1889.
13. Ebiloma GU, Díaz-Ayuga T, Balogun EO, et al. Inhibition of trypanosome alternative 
oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic 
and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active 
against T. brucei and T. congolense. Eur J Med Chem. 2018;150:385-402.
Page 60 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
14. Chaudhuri M, Ott RD, Hill GC. Trypanosome alternative oxidase: from molecule to 
function. Trends Parasitol. 2006;22(10):484-491.
15. Nihei C, Fukai Y, Kita K. Trypanosome alternative oxidase as a target of chemotherapy. 
Biochim Biophys Acta. 2002;1587(2-3):234-239.
16. Chaudhuri M, Ajayi W, Hill GC. Biochemical and molecular properties of the 
Trypanosoma brucei alternative oxidase. Mol Biochem Parasitol. 1998;95(1):53-68.
17. Clarkson AB, Jr., Bienen EJ, Pollakis G, Grady RW. Respiration of bloodstream forms 
of the parasite Trypanosoma brucei brucei is dependent on a plant-like alternative 
oxidase. J Biol Chem. 1989;264(30):17770-17776.
18. Menzies SK, Tulloch LB, Florence GJ, Smith TK. The trypanosome alternative oxidase: 
a potential drug target? Parasitology. 2016;145(2):175-183.
19. Murphy AD, Lang-Unnasch N. Alternative Oxidase Inhibitors Potentiate the Activity of 
Atovaquone against Plasmodium falciparum. Antimicrob Agents Chemother. 
1999;43(3):651-654.
20. Murphy AD, Doeller JE, Hearn B, Lang-Unnasch N. Plasmodium falciparum: Cyanide-
Resistant Oxygen Consumption. Exp Parasitol. 1997;87(2):112-120.
21. Kissinger JC, Gajria B, Li L, Paulsen IT, Roos DS. ToxoDB: accessing the Toxoplasma 
gondii genome. Nucl Acids Res. 2003;31(1):234-236.
22. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite 
Plasmodium falciparum. Nature. 2002;419:498-511.
23. Suzuki T, Hashimoto T, Yabu Y, et al. Direct evidence for cyanide-insensitive quinol 
oxidase (alternative oxidase) in apicomplexan parasite Cryptosporidium parvum: 
Phylogenetic and therapeutic implications. Biochem Biophys Res Commun. 
2004;313(4):1044-1052.
24. King P, Robinson G, Elwin K, Tyler KM, Hunter PR, Chalmers RM. Prevalence and 
epidemiology of human Cryptosporidium parvum IIc infections in England and Wales. 
Lancet. 2017;389:S56.
25. Hunter PR, Nichols G. Epidemiology and Clinical Features of Cryptosporidium Infection 
in Immunocompromised Patients. Clin Microbiol Rev. 2002;15(1):145-154.
26. Müller M, Mentel M, van Hellemond JJ, et al. Biochemistry and Evolution of Anaerobic 
Energy Metabolism in Eukaryotes. Microbiol Mol Biol Rev. 2012;76(2):444-495.
27. Suzuki T, Nihei C, Yabu Y, et al. Molecular cloning and characterization of Trypanosoma 
vivax alternative oxidase (AOX) gene, a target of the trypanocide ascofuranone. 
Parasitology international. 2004;53(3):235-245.
28. Alkhaldi AAM, Martinek J, Panicucci B, Dardonville C, Zíková A, de Koning HP. 
Trypanocidal action of bisphosphonium salts through a mitochondrial target in 
Page 61 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
62
bloodstream form Trypanosoma brucei. Int J Parasitol Drugs Drug Resist. 2016;6(1):23-
34.
29. Rodenko B, Wanner MJ, Alkhaldi AAM, et al. Targeting the Parasite's DNA with 
Methyltriazenyl Purine Analogs Is a Safe, Selective, and Efficacious Antitrypanosomal 
Strategy. Antimicrob Agents Chemother. 2015;59(11):6708-6716.
30. Jamonneau V, Ilboudo H, Kaboré J, et al. Untreated Human Infections by Trypanosoma 
brucei gambiense Are Not 100% Fatal. PLOS Negl Trop Dis. 2012;6(6):e1691.
31. Deborggraeve S, Koffi M, Jamonneau V, et al. Molecular analysis of archived blood 
slides reveals an atypical human Trypanosoma infection. Diagnostic Microbiol Infect 
Dis. 2008;61(4):428-433.
32. Wolf T, Wichelhaus T, Göttig S, Kleine C, Brodt H, Just-Nuebling G. Trypanosoma 
brucei rhodesiense infection in a German traveller returning from the Masai Mara area, 
Kenya. Euro Surveill 2012;17(10):20114.
33. Gautret P, Clerinx J, Caumes E, et al. Imported human African trypanosomiasis in 
Europe, 2005-2009. Eurosurveillance. 2009;14(36):19327.
34. Moore AL, Siedow JN. The regulation and nature of the cyanide-resistant alternative 
oxidase of plant mitochondria. Biochim Biophys Acta (BBA) - Bioenergetics. 
1991;1059(2):121-140.
35. Schmucker T. Beiträge zur Biologie und Physiologie von Arum maculatum. Flora 
1925;118: 460-475 
36. Miller RE, Grant NM, Giles L, et al. In the heat of the night – alternative pathway 
respiration drives thermogenesis in Philodendron bipinnatifidum. New Phytol. 
2011;189:1013-1026.
37. Wagner AM, Krab K, Wagner MJ, Moore AL. Regulation of thermogenesis in flowering 
Araceae: The role of the alternative oxidase. Biochim Biophys Acta (BBA) - 
Bioenergetics. 2008;1777(7):993-1000.
38. Watling JR, Robinson SA, Seymour RS. Contribution of the Alternative Pathway to 
Respiration during Thermogenesis in Flowers of the Sacred Lotus. Plant Physiol. 
2006;140(4):1367-1373.
39. Gardeström P, Igamberdiev AU, Raghavendra AS. Mitochondrial functions in the light 
and significance to carbon-nitrogen interactions. . In: Photosynthetic nitrogen 
assimilation and associated carbon and respiratory metabolism. Dordrecht: Springer; 
2002: 151-172.
40. Royo B, Moran JF, Ratcliffe RG, Gupta KJ. Nitric oxide induces the alternative oxidase 
pathway in Arabidopsis seedlings deprived of inorganic phosphate. J Exp Botany. 
2015;66(20):6273-6280.
Page 62 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
63
41. Maxwell DP, Wang Y, McIntosh L. The alternative oxidase lowers mitochondrial 
reactive oxygen production in plant cells. Proc Nat Acad Sci USA. 1999;96(14):8271-
8276.
42. Millar AH, Day DA. Nitric oxide inhibits the cytochrome oxidase but not the alternative 
oxidase of plant mitochondria. FEBS Lett. 1996;398(2-3):155-158.
43. Millenaar FF, Lambers H. The Alternative Oxidase: in vivo Regulation and Function. 
Plant Biol. 2008;5(1):2-15.
44. Rychter AM, Szal B. Alternative pathways and phosphate and nitrogen nutrition. In: 
Wiley-Blackwell, ed. Alternative Respiratory Pathways in Higher Plants.2015:53.
45. Kido Y, Sakamoto K, Nakamura K, et al. Purification and kinetic characterization of 
recombinant alternative oxidase from Trypanosoma brucei brucei. Biochim Biophys 
Acta, Bioenerg. 2010;1797(4):443-450.
46. McDonald AE, Vanlerberghe GC, Staples JF. Alternative oxidase in animals: unique 
characteristics and taxonomic distribution. J Exp Biol. 2009;212(16):2627-2634.
47. Bruce D. Preliminary report on the tsetse fly disease or nagana, in Zululand. Bennett & 
Davis; 1895.
48. Steverding D. The history of African trypanosomiasis. Parasit Vectors. 2008;1(1):3.
49. Smith T, Bringaud F, Nolan D, Figueiredo L. Metabolic reprogramming during the 
Trypanosoma brucei life cycle. F1000Research. 2017;6(683).
50. Hill GC. Electron transport systems in kinetoplastida. Biochim Biophys Acta (BBA) - Rev 
Bioenerg. 1976;456(2):149-193.
51. Grant PT, Sargent JR. Properties of L-alpha-glycerophosphate oxidase and its role in the 
respiration of Trypanosoma rhodesiense. Biochem J. 1960;76:229-237.
52. Opperdoes FR, Borst P, Bakker S, Leene W. Localization of glycerol-3-phosphate 
oxidase in the mitochondrion and particulate NAD+-linked glycerol-3-phosphate 
dehydrogenase in the microbodies of the bloodstream form to Trypanosoma brucei. Eur 
J Biochem. 1977;76(1):29-39.
53. Fairlamb AH, Bowman IBR. The isolation and characterisation of particulate sn-glycerol-
3-phosphate oxidase from Trypanosoma brucei. Int J Biochem. 1977;8(9):659-668.
54. Minagawa N, Yabu Y, Kita K, et al. An antibiotic, ascofuranone, specifically inhibits 
respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei 
brucei. Mol Biochem Parasitol. 1996;81(2):127-136.
55. Evans DA, Brown RC. The inhibitory effects of aromatic hydroxamic acids on the 
cyanide-insensitive terminal oxidase of Trypanosoma brucei. Trans R Soc Trop Med Hyg. 
1973;67(2):258.
56. Chaudhuri M, Ajayi W, Temple S, Hill GC. Identification and partial purification of a 
stage-specific 33 kDa mitochondrial protein as the alternative oxidase of the 
Page 63 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
64
Trypanosoma brucei brucei bloodstream trypomastigotes. J Eukaryot Microbiol. 
1995;42(5):467-472.
57. Chaudhuri M, Hill GC. Cloning, sequencing, and functional activity of the Trypanosoma 
brucei brucei alternative oxidase. Mol Biochem Parasitol. 1996;83(1):125-129.
58. Hamilton V, Singha UK, Smith JT, Weems E, Chaudhuri M. Trypanosome Alternative 
Oxidase Possesses both an N-Terminal and Internal Mitochondrial Targeting Signal. 
Eukaryot Cell. 2014;13(4):539-547.
59. Saimoto H, Kido Y, Haga Y, Sakamoto K, Kita K. Pharmacophore identification of 
ascofuranone, potent inhibitor of cyanide-insensitive alternative oxidase of Trypanosoma 
brucei. J Biochem. 2013;153(3):267-273.
60. Shiba T, Kido Y, Sakamoto K, et al. Crystal structure of the alternative oxidases: New 
insights into the catalytic cycle. Biochim Biophys Acta (BBA) - Bioenergetics. 2012;1817, 
Supplement(0):S102-S103.
61. Kido Y, Shiba T, Inaoka DK, et al. Crystallization and preliminary crystallographic 
analysis of cyanide-insensitive alternative oxidase from Trypanosoma brucei brucei. Acta 
Cryst F. 2010;66(Pt 3):275-278.
62. Fueyo González FJ, Ebiloma GU, Izquierdo García C, et al. Conjugates of 2,4-
Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Anti-
parasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma 
congolense Mitochondrion. J Med Chem. 2017;60:1509-1522.
63. Siedow JN, Umbach AL. The mitochondrial cyanide-resistant oxidase: structural 
conservation amid regulatory diversity. Biochim Biophys Acta - Bioenergetics. 
2000;1459(2):432-439.
64. Tielens AG, van Hellemond JJ. Surprising variety in energy metabolism within 
Trypanosomatidae. Trends Parasitol. 2009;25(10):482-490.
65. Eze AA, Gould MK, Munday JC, et al. Reduced Mitochondrial Membrane Potential Is a 
Late Adaptation of Trypanosoma brucei brucei to Isometamidium Preceded by Mutations 
in the gamma Subunit of the F1Fo-ATPase. PLoS Negl Trop Dis. 2016;10(8):e0004791.
66. Schnaufer A, Clark-Walker GD, Steinberg AG, Stuart K. The F1-ATP synthase complex 
in bloodstream stage trypanosomes has an unusual and essential function. The EMBO 
journal. 2005;24(23):4029-4040.
67. Chaudhuri M, Sharan R, Hill GC. Trypanosome alternative oxidase is regulated post-
transcriptionally at the level of RNA stability. J Eukaryot Microbiol. 2002;49(4):263-
269.
68. Tetaud E, Barrett MP, Bringaud F, Baltz T. Kinetoplastid glucose transporters. Biochem 
J. 1997;325 ( Pt 3):569-580.
Page 64 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
65
69. Michels PA, Bringaud F, Herman M, Hannaert V. Metabolic functions of glycosomes in 
trypanosomatids. Biochim Biophys Acta. 2006;1763(12):1463-1477.
70. Sanchez MA. Molecular identification and characterization of an essential pyruvate 
transporter from Trypanosoma brucei. J Biol Chem. 2013;288(20):14428-14437.
71. Opperdoes FR. Compartmentation of Carbohydrate Metabolism in Trypanosomes. Ann 
Rev Microbiol. 1987;41(1):127-151.
72. Helfert S, Estevez AM, Bakker B, Michels P, Clayton C. Roles of triosephosphate 
isomerase and aerobic metabolism in Trypanosoma brucei. Biochem J. 2001;357(Pt 
1):117-125.
73. Balogun EO, Inaoka DK, Shiba T, et al. Glycerol kinase of African trypanosomes 
possesses an intrinsic phosphatase activity. Biochim Biophys Acta. 2017;1861(11, Part 
A):2830-2842.
74. Yabu Y, Suzuki T, Nihei C, et al. Chemotherapeutic efficacy of ascofuranone in 
Trypanosoma vivax-infected mice without glycerol. Parasitol Int. 2006;55(1):39-43.
75. Walker R, Saha L, Hill GC, Chaudhuri M. The effect of over-expression of the alternative 
oxidase in the procyclic forms of Trypanosoma brucei. Mol Biochem Parasitol. 
2005;139(2):153-162.
76. Fang J, Beattie DS. Alternative oxidase present in procyclic Trypanosoma brucei may act 
to lower the mitochondrial production of superoxide. Arch Biochem Biophys. 
2003;414(2):294-302.
77. Tsuda A, Witola WH, Ohashi K, Onuma M. Expression of alternative oxidase inhibits 
programmed cell death-like phenomenon in bloodstream form of Trypanosoma brucei 
rhodesiense. Parasitol Int. 2005;54(4):243-251.
78. Vassella E, Oberle M, Urwyler S, et al. Major Surface Glycoproteins of Insect Forms of 
Trypanosoma brucei Are Not Essential for Cyclical Transmission by Tsetse. PLoS ONE. 
2009;4(2):e4493.
79. Bütikofer P, Ruepp S, Boschung M, Roditi I. ‘GPEET’ procyclin is the major surface 
protein of procyclic culture forms of Trypanosoma brucei brucei strain 427. Biochem J. 
1997;326(2):415.
80. Vassella E, Den Abbeele JV, Bütikofer P, et al. A major surface glycoprotein of 
Trypanosoma brucei is expressed transiently during development and can be regulated 
post-transcriptionally by glycerol or hypoxia. Genes Develop. 2000;14(5):615-626.
81. Vassella E, Probst M, Schneider A, Studer E, Renggli CK, Roditi I. Expression of a Major 
Surface Protein of Trypanosoma brucei Insect Forms Is Controlled by the Activity of 
Mitochondrial Enzymes. Mol Biol Cell. 2004;15(9):3986-3993.
Page 65 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
66
82. Pennisi R, Salvi D, Brandi V, Angelini R, Ascenzi P, Polticelli F. Molecular Evolution 
of Alternative Oxidase Proteins: A Phylogenetic and Structure Modeling Approach. J 
Mol Evol. 2016;DOI 10.1007/s00239-016-9738-8:1-12.
83. Stechmann A, Hamblin K, Pérez-Brocal V, et al. Organelles in Blastocystis that Blur the 
Distinction between Mitochondria and Hydrogenosomes. Curr Biol. 2008;18(8):580-
585.
84. Selinski J, Scheibe R, Day DA, Whelan J. Alternative Oxidase Is Positive for Plant 
Performance. Trends Plant Sci. 2018;23(7):588-597.
85. Stenmark P, Nordlund P. A prokaryotic alternative oxidase present in the bacterium 
Novosphingobium aromaticivorans. FEBS Lett. 2003;552(2):189-192.
86. Moore AL, Albury MS, Crichton PG, Affourtit C. Function of the alternative oxidase: is 
it still a scavenger? Trends Plant Sci. 2002;7(11):478-481.
87. Mizutani A, Yukioka H, Tamura H, Miki N, Masuko M, Takeda R. Respiratory 
characteristics of Pyricularia oryzae exposed to a novel alkoxyiminoacetamide. 
Physiopathol. 1995;85(2):271-280.
88. Yukioka H, Inagaki S, Tanaka R, et al. Transcriptional activation of the alternative 
oxidase gene of the fungus Magnaporthe grisea by a respiratory-inhibiting fungicide and 
hydrogen peroxide. Biochim Biophys Acta (BBA) - Gene Structure and Expression. 
1998;1442(2):161-169.
89. Honda Y, Hattori T, Kirimura K. Visual expression analysis of the responses of the 
alternative oxidase gene (aox1) to heat shock, oxidative, and osmotic stresses in conidia 
of citric acid-producing Aspergillus niger. J Biosci Bioeng. 2012;113(3):338-342.
90. Magnani T, Soriani FM, Martins VP, et al. Cloning and functional expression of the 
mitochondrial alternative oxidase of Aspergillus fumigatus and its induction by oxidative 
stress. FEMS Microbiol Lett. 2007;271(2):230-238.
91. Minagawa N, Koga S, Nakano M, Sakajo S, Yoshimoto A. Possible involvement of 
superoxide anion in the induction of cyanide-resistant respiration in Hansenula anomala. 
FEBS Lett. 1992;302(3):217-219.
92. Martins VP, Dinamarco TM, Soriani FM, et al. Involvement of an Alternative Oxidase in 
Oxidative Stress and Mycelium-to-Yeast Differentiation in Paracoccidioides 
brasiliensis. Eukaryot Cell. 2011;10(2):237-248.
93. Biryukova EN, Medentsev AG, Arinbasarova AY, Akimenko VK. Respiratory activity 
of yeast Yarrowia lipolytica under oxidative stress and heat shock. Microbiol. 
2008;77(4):395-399.
94. Hernández Ruiz O, Gonzalez A, Almeida AJ, et al. Alternative Oxidase Mediates 
Pathogen Resistance in Paracoccidioides brasiliensis Infection. PLOS Negl Trop Dis. 
2011;5(10):e1353.
Page 66 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
67
95. Akhter S, McDade HC, Gorlach JM, Heinrich G, Cox GM, Perfect JR. Role of alternative 
oxidase gene in pathogenesis of Cryptococcus neoformans. Infect Immun. 
2003;71(10):5794-5802.
96. Dean R, Van Kan JAL, Pretorius ZA, et al. The Top 10 fungal pathogens in molecular 
plant pathology. Mol Plant Pathol. 2012;13(4):414-430.
97. Brefort T, Doehlemann G, Mendoza-Mendoza A, Reissmann S, Djamei A, Kahmann R. 
Ustilago maydis as a Pathogen. Ann Rev Phytopathol. 2009;47(1):423-445.
98. Guerrero-Castillo S, Cabrera-Orefice A, Vázquez-Acevedo M, González-Halphen D, 
Uribe-Carvajal S. During the stationary growth phase, Yarrowia lipolytica prevents the 
overproduction of reactive oxygen species by activating an uncoupled mitochondrial 
respiratory pathway. Biochim Biophys Acta (BBA) - Bioenergetics. 2012;1817(2):353-
362.
99. Juárez O, Guerra G, Velázquez I, Flores-Herrera O, Rivera-Pérez RE, Pardo JP. The 
physiologic role of alternative oxidase in Ustilago maydis. FEBS J. 2006;273(20):4603-
4615.
100. Cárdenas-Monroy CA, Pohlmann T, Piñón-Zárate G, et al. The mitochondrial alternative 
oxidase Aox1 is needed to cope with respiratory stress but dispensable for pathogenic 
development in Ustilago maydis. PloS ONE. 2017;12(3):e0173389.
101. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug 
Discov Today. 2011;16(23-24):1037-1043.
102. Jones LH. An industry perspective on drug target validation. Expert opinion on drug 
discovery. 2016;11(7):623-625.
103. Ohashi-Suzuki M, Yabu Y, Ohshima S, et al. Differential kinetic activities of glycerol 
kinase among African trypanosome species: phylogenetic and therapeutic implications. J 
Vet Med Sci. 2011;73(5):615-621.
104. Takumi S, Tomioka M, Eto K, Naydenov N, Nakamura C. Characterization of two non-
homoeologous nuclear genes encoding mitochondrial alternative oxidase in common 
wheat. Genes & genetic systems. 2002;77(2):81-88.
105. Zalutskaya Z, Filina V, Ostroukhova M, Ermilova E. Regulation of alternative oxidase 1 
in Chlamydomonas reinhardtii during sulfur starvation. Eur J Protistol. 2018;63:26-33.
106. Brew-Appiah RAT, York ZB, Krishnan V, Roalson EH, Sanguinet KA. Genome-wide 
identification and analysis of the ALTERNATIVE OXIDASE gene family in diploid and 
hexaploid wheat. PLoS One. 2018;13(8):e0201439.
107. Kita K, Konishi K, Anraku Y. Terminal oxidases of Escherichia coli aerobic respiratory 
chain. II. Purification and properties of cytochrome b558-d complex from cells grown 
with limited oxygen and evidence of branched electron-carrying systems. J Biol Chem. 
1984;259(5):3375-3381.
Page 67 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
68
108. Tsubaki M, Hori H, Mogi T. Glutamate-286 mutants of cytochrome bo-type ubiquinol 
oxidase from Escherichia coli: influence of mutations on the binuclear center structure 
revealed by FT-IR and EPR spectroscopies. FEBS letters. 1997;416(3):247-250.
109. Fukai Y, Amino H, Hirawake H, et al. Functional expression of the ascofuranone-
sensitive Trypanosoma brucei brucei alternative oxidase in the cytoplasmic membrane of 
Escherichia coli. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 
1999;124(2):141-148.
110. Ajayi WU, Chaudhuri M, Hill GC. Site-directed mutagenesis reveals the essentiality of 
the conserved residues in the putative diiron active site of the trypanosome alternative 
oxidase. J Biol Chem. 2002;277(10):8187-8193.
111. Tobie EJ, Von Brand T, Mehlman B. Cultural and physiological observations on 
Trypanosoma rhodesiense and Trypanosoma gambiense. J Parasitol. 1950;36(1):48-54.
112. Nihashi N, Inaoka DK, Tsuge C, et al. Siccanin Is a Novel Selective Inhibitor of 
Trypanosomatid Complex II (Succinate-Ubiquinone Reductase) and a Potent Broad-
Spectrum Anti-trypanosomatid Drug Candidate. In: Noiri E, Jha TK, eds. Kala Azar in 
South Asia: Current Status and Sustainable Challenges. Cham: Springer International 
Publishing; 2016:101-122.
113. Minagawa N, Yabu Y, Kita K, et al. An antibiotic, ascofuranone, specifically inhibits 
respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei 
brucei. Mol Biochem Parasitol. 1997;84(2):271-280.
114. Yang G, Zhu W, Kim K, et al. In Vitro and In Vivo Investigation of the Inhibition of 
Trypanosoma brucei Cell Growth by Lipophilic Bisphosphonates. Antimicrob Agents 
Chemother. 2015;59(12):7530-7539.
115. Gould MK, Vu XL, Seebeck T, de Koning HP. Propidium iodide-based methods for 
monitoring drug action in the kinetoplastidae: Comparison with the Alamar Blue assay. 
Anal Biochem. 2008;382(2):87-93.
116. Räz B, Iten M, Grether-Bühler Y, Kaminsky R, Brun R. The Alamar Blue assay to 
determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. 
gambiense) in vitro. Acta Trop. 1997;68(2):139-147.
117. Schonbaum GR, Bonner WD, Storey BT, Bahr JT. Specific Inhibition of the Cyanide-
insensitive Respiratory Pathway in Plant Mitochondria by Hydroxamic Acids. Plant 
Physiology. 1971;47(1):124-128.
118. Tyler KM, Matthews KR, Gull K. The bloodstream differentiation-division of 
Trypanosoma brucei studied using mitochondrial markers. Proc Biol Sci. 
1997;264(1387):1481-1490.
119. Opperdoes FR, Aarsen PN, van der Meer C, Borst P. Trypanosoma brucei: an evaluation 
of salicylhydroxamic acid as a trypanocidal drug. Exp Parasitol. 1976;40(2):198-205.
Page 68 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
69
120. Fairlamb AH, Opperdoes FR, Borst P. New approach to screening drugs for activity 
against African trypanosomes. Nature. 1977;265(5591):270-271.
121. Van Der Meer C, Versluijs-Broers JA. Trypanosoma brucei: trypanocidal effect of 
salicylhydroxamic acid plus glycerol in infected rats. Exp Parasitol. 1979;48(1):126-134.
122. Njogu RM, Whittaker CJ, Hill GC. Evidence for a branched electron transport chain in 
Trypanosoma brucei. Mol Biochem Parasitol. 1980;1(1):13-29.
123. Grady RW, Bienen EJ, Clarkson AB, Jr. p-Alkyloxybenzhydroxamic acids, effective 
inhibitors of the trypanosome glycerol-3-phosphate oxidase. Mol Biochem Parasitol. 
1986;19(3):231-240.
124. Clarkson AB, Jr., Grady RW, Grossman SA, McCallum RJ, Brohn FH. Trypanosoma 
brucei brucei: a systematic screening for alternatives to the salicylhydroxamic acid-
glycerol combination. Mol Biochem Parasitol. 1981;3(5):271-291.
125. Grady RW, Bienen EJ, Clarkson AB, Jr. Esters of 3,4-dihydroxybenzoic acid, highly 
effective inhibitors of the sn-glycerol-3-phosphate oxidase of Trypanosoma brucei 
brucei. Mol Biochem Parasitol. 1986;21(1):55-63.
126. Meco-Navas A, Ebiloma GU, Martín-Domínguez A, et al. SAR of 4-Alkoxybenzoic Acid 
Inhibitors of the Trypanosome Alternative Oxidase. ACS Med Chem Lett. 2018;9(9):923-
928.
127. Clarkson AB, Jr., Brohn FH. Trypanosomiasis: an approach to chemotherapy by the 
inhibition of carbohydrate catabolism. Science (New York, NY. 1976;194(4261):204-206.
128. Brohn FH, Clarkson AB, Jr. Quantitative effects of salycylhydroxamic acid and glycerol 
on Trypanosoma brucei glycolysis in vitro and in vivo. Acta Trop. 1978;35(1):23-33.
129. Yabu Y, Nose M, Koide T, Ohta N, Ogihara Y. Antitrypanosomal effects of traditional 
Chinese herbal medicines on bloodstream forms of Trypanosoma brucei rhodesiense in 
vitro. Southeast Asian J Trop Med Public Health. 1998;29(3):599-604.
130. Yabu Y, Yoshida A, Suzuki T, et al. The efficacy of ascofuranone in a consecutive 
treatment on Trypanosoma brucei brucei in mice. Parasitol Int. 2003;52(2):155-164.
131. Giroud C, Ottones F, Coustou V, et al. Murine Models for Trypanosoma brucei 
gambiense disease progression--from silent to chronic infections and early brain tropism. 
PLoS Negl Trop Dis. 2009;3(9):e509.
132. Trindade S, Rijo-Ferreira F, Carvalho T, et al. Trypanosoma brucei Parasites Occupy and 
Functionally Adapt to the Adipose Tissue in Mice. Cell Host Microbe. 2016;19(6):837-
848.
133. Carvalho T, Trindade S, Pimenta S, Santos AB, Rijo-Ferreira F, Figueiredo LM. 
Trypanosoma brucei triggers a marked immune response in male reproductive organs. 
PLoS Negl Trop Dis. 2018;12(8):e0006690.
Page 69 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
70
134. van der Meer C, Versluys-Broers JA, van Duin CT, van den Ingh TS, Nieuwenhuijs J, 
Zwart D. Pitfalls of salicylhydroxamic acid plus glycerol treatment of T. vivax infected 
goats. Tropenmedizin und Parasitologie. 1980;31(3):275-282.
135. Evans DA, Brightman CJ, Holland MF. Salicylhydroxamic-acid/glycerol in experimental 
trypanosomiasis. Lancet. 1977;2(8041):769.
136. Evans DA, Brightman CA. Pleomorphism and the problem of recrudescent parasitaemia 
following treatment with salicylhydroxamic acid (SHAM) in African trypanosomiasis. 
Trans R Soc Trop Med Hyg. 1980;74(5):601-604.
137. Yabu Y, Minagawa N, Kita K, et al. Oral and intraperitoneal treatment of Trypanosoma 
brucei brucei with a combination of ascofuranone and glycerol in mice. Parasitol Int. 
1998;47(2):131-137.
138. Jackson DA, Symons RH, Berg P. Biochemical method for inserting new genetic 
information into DNA of Simian Virus 40: circular SV40 DNA molecules containing 
lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl Acad Sci 
USA. 1972;69(10):2904-2909.
139. Cohen SN, Chang AC, Boyer HW, Helling RB. Construction of biologically functional 
bacterial plasmids in vitro. Proc. Natl Acad Sci USA. 1973;70(11):3240-3244.
140. Chang AC, Cohen SN. Genome construction between bacterial species in vitro: 
replication and expression of Staphylococcus plasmid genes in Escherichia coli. Proc. 
Natl Acad Sci USA. 1974;71(4):1030-1034.
141. Acestor N, Panigrahi AK, Ogata Y, Anupama A, Stuart KD. Protein composition of 
Trypanosoma brucei mitochondrial membranes. Proteomics. 2009;9(24):5497-5508.
142. Jakob M, Hoffmann A, Amodeo S, Peitsch C, Zuber B, Ochsenreiter T. Mitochondrial 
growth during the cell cycle of Trypanosoma brucei bloodstream forms. Sci Rep. 
2016;6:36565.
143. Fukai Y, Nihei C, Kawai K, et al. Overproduction of highly active trypanosome 
alternative oxidase in Escherichia coli heme-deficient mutant. Parasitol Int. 
2003;52(3):237-241.
144. Nihei C, Fukai Y, Kawai K, et al. Purification of active recombinant trypanosome 
alternative oxidase. FEBS letters. 2003;538(1-3):35-40.
145. Nihei C, Nakayashiki T, Nakamura K, et al. Abortive assembly of succinate-ubiquinone 
reductase (complex II) in a ferrochelatase-deficient mutant of Escherichia coli. Mol. 
Genet Genomics. 2001;265(3):394-404.
146. Nakamura K, Fujioka S, Fukumoto S, et al. Trypanosome alternative oxidase, a potential 
therapeutic target for sleeping sickness, is conserved among Trypanosoma brucei 
subspecies. Parasitol Int. 2010;59(4):560-564.
Page 70 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
71
147. Sharpless TK, Butow RA. An inducible alternate terminal oxidase in Euglena gracilis 
mitochondria. J Biol Chem. 1970;245(1):58-70.
148. Baker JE. Diphenylamine Inhibition of Electron Transport in Plant Mitochondria. Arch 
Biochem Biophys. 1963;103:148-155.
149. Evans DA, Brown RC. The effect of diphenylamine on terminal respiration in 
bloodstream and culture forms of Trypanosoma brucei. J Protozool. 1972;19(2):365-369.
150. Evans DA, Brown RC. m-Chlorobenzhydroxyamic acid--an inhibitor of cyanide-
insensitive respiration in Trypanosoma brucei. J Protozool. 1973;20(1):157-160.
151. Opperdoes FR, Borst P, Fonck K. The potential use of inhibitors of glycerol-3-phosphate 
oxidase for chemotherapy of African trypanosomiasis. FEBS letters. 1976;62(2):169-
172.
152. Kunze B, Hofle G, Reichenbach H. The aurachins, new quinoline antibiotics from 
myxobacteria: production, physico-chemical and biological properties. J Antibiot. 
1987;40(3):258-265.
153. Hoefnagel MHN, Wiskich JT, Madgwick SA, Patterson Z, Oettmeier W, Rich PR. New 
Inhibitors of the Ubiquinol Oxidase of Higher Plant Mitochondria. Eur J Biochem. 
1995;233(2):531-537.
154. Miyoshi H, Takegami K, Sakamoto K, Mogi T, Iwamura H. Characterization of the 
Ubiquinol Oxidation Sites in Cytochromes bo and bd from Escherichia coli using 
Aurachin C Analogues. J Biochem. 1999;125(1):138-142.
155. Mogi T, Ui H, Shiomi K, Ōmura S, Miyoshi H, Kita K. Antibiotics LL-Z1272 identified 
as novel inhibitors discriminating bacterial and mitochondrial quinol oxidases. Biochim 
Biophys Acta - Bioenergetics. 2009;1787(2):129-133.
156. Siedow JN, Bickett DM. Structural features required for inhibition of cyanide-insensitive 
electron transfer by propyl gallate. Archiv Biochem Biophys. 1981;207(1):32-39.
157. Ott R, Chibale K, Anderson S, et al. Novel inhibitors of the trypanosome alternative 
oxidase inhibit Trypanosoma brucei brucei growth and respiration. Acta Trop. 
2006;100(3):172-184.
158. Grady RW, Bienen EJ, Dieck HA, Saric M, Clarkson AB, Jr. N-n-alkyl-3,4-
dihydroxybenzamides as inhibitors of the trypanosome alternative oxidase: activity in 
vitro and in vivo. Antimicrob Agents Chemother. 1993;37(5):1082-1085.
159. West RA, O'Doherty OG, Askwith T, et al. African trypanosomiasis: Synthesis & SAR 
enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase. 
Eur J Med Chem. 2017;141(Supplement C):676-689.
160. West RA, Cunningham T, Pennicott LE, Rao SPS, Ward SE. Toward More Drug Like 
Inhibitors of Trypanosome Alternative Oxidase. ACS Infect Dis. 2018;4(4):592-604.
Page 71 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
72
161. Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond Rules: The Development 
of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To 
Enable Alignment of Druglike Properties. ACS Chem Neurosci. 2010;1(6):435-449.
162. Rogov AG, Sukhanova EI, Uralskaya LA, Aliverdieva DA, Zvyagilskaya RA. 
Alternative oxidase: Distribution, induction, properties, structure, regulation, and 
functions. Biochem (Moscow). 2014;79(13):1615-1634.
163. Charles A, G. WD, L. MA. Maesaquinone: A Novel Inhibitor of Plant Mitochondrial 
Respiratory Enzymes That React with Ubiquinone. IUBMB Life. 2000;49(6):533-537.
164. Turrens JF, Bickar D, Lehninger AL. Inhibitors of the mitochondrial cytochrome b-c1 
complex inhibit the cyanide-insensitive respiration of Trypanosoma brucei. Mol Biochem 
Parasitol. 1986;19(3):259-264.
165. Carboni S, Malaguzzi V, Marsili A. Ferulenol a new coumarin derivative from Ferula 
communis. Tetrahedron Lett. 1964;5(38):2783-2786.
166. Appendino G, Mercalli E, Fuzzati N, et al. Antimycobacterial Coumarins from the 
Sardinian Giant Fennel (Ferula communis). J Nat Prod. 2004;67(12):2108-2110.
167. Hartuti ED, Inaoka DK, Komatsuya K, et al. Biochemical studies of membrane bound 
Plasmodium falciparum mitochondrial L-malate:quinone oxidoreductase, a potential 
drug target. Biochim Biophys Acta - Bioenergetics. 2018;1859(3):191-200.
168. Kosuge Y, Suzuki A, Tamura S. Structures of Colletochlorin C, Colletorin A and 
Colletorin C from Colletotrichum nicotianae. Agr Biol Chem. 1974;38(6):1265-1267.
169. Takamatsu S, Rho M-C, Masuma R, et al. A Novel Testosterone 5a-Reductase Inhibitor, 
8',9'-Dehydroascochlorin Produced by Verticillium sp. FO-2787. Chem Pharm Bull. 
1994;42(4):953-956.
170. Andersson ME, Nordlund P. A revised model of the active site of alternative oxidase. 
FEBS letters. 1999;449(1):17-22.
171. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein 
prostaglandin H2 synthase-1. Nature. 1994;367(6460):243-249.
172. Gupta K, Selinsky BS, Kaub CJ, Katz AK, Loll PJ. The 2.0 A resolution crystal structure 
of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase. J. Mol. 
Biol. 2004;335(2):503-518.
173. Berthold DA, Voevodskaya N, Stenmark P, Graslund A, Nordlund P. EPR studies of the 
mitochondrial alternative oxidase. Evidence for a diiron carboxylate center. J Biol Chem. 
2002;277(46):43608-43614.
174. Nordlund P, Eklund H. Di-iron-carboxylate proteins. Curr Opin Struct. Biol. 
1995;5(6):758-766.
175. Sasaki H, Okutomi T, Hosokawa T, Nawata Y, Ando K. Ascofuranone, a new antibiotic 
from Ascochyta viciae. Tetrahedron Lett. 1972;13(25):2541-2544.
Page 72 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
73
176. Hijikawa Y, Matsuzaki M, Suzuki S, et al. Re-identification of the ascofuranone-
producing fungus Ascochyta viciae as Acremonium sclerotigenum. J Antibiot. 
2016;70:304.
177. Saimoto H, Hiyama T. A general highly efficient access to prenylated phenolic natural 
products. Synthesis of colletochlorins B and D. Tetrahedron Lett. 1986;27(5):597-600.
178. Ima-ye K, Kakisawa H. Synthesis of grifolin and dihydrodeoxytauranin. J Chem Soc, 
Perkin Trans 1. 1973(0):2591-2595.
179. Mori K, Fujioka T. Synthesis of (±)-ascochlorin, (±)-ascofuranone and LL-Z1272. 
Tetrahedron. 1984;40(14):2711-2720.
180. Chen K-M, Joullié MM. A simple total synthesis of (±)-ascofuranone. Tetrahedron Lett. 
1984;25(35):3795-3796.
181. Ohta S, Nozaki A, Ohashi N, Matsukawa M, Okamoto M. A Total Synthesis of Grifolin. 
Chem Pharm Bull. 1988;36(6):2239-2243.
182. Mori K, Fujioka T. Synthesis of (±)-ascofuranone, in antibiotic with hypolipidemic and 
antitumor protective properties. Tetrahedron Lett. 1983;24(14):1547-1548.
183. Guthrie AA, Semple JE, Joullie MM. Synthetic studies of fungal metabolites: 
ascofuranone and colletochlorin D. J Org Chem. 1982;47(12):2369-2376.
184. Mori K, Takechi S. Synthesis of the natural enantiomers of ascochlorin, ascofuranone 
and ascofuranol. Tetrahedron. 1985;41(15):3049-3062.
185. Saimoto H, Ohrai S-i, Sashiwa H, Shigemasa Y, Hiyama T. Total Synthesis of dl-
Ascofuranone and Related Compounds. Bull Chem Soc Jap. 1995;68(9):2727-2734.
186. Shigemasa Y, Yasui M, Ohrai S, Sasaki M, Sashiwa H, Saimoto H. Enantioselective 
transformation of propargyl esters to dihydrofurans. J Org Chem. 1991;56(3):910-912.
187. Dudley GB, Takaki KS, Cha DD, Danheiser RL. Total Synthesis of (−)-Ascochlorin via 
a Cyclobutenone-Based Benzannulation Strategy. Org Lett. 2000;2(21):3407-3410.
188. Haga Y, Tonoi T, Anbiru Y, et al. A short and efficient total synthesis of (±)-
ascofuranone. Chem Lett. 2010;39(6):622-623.
189. Grabovyi GA, Mohr JT. Total Synthesis of Grifolin, Grifolic Acid, LL-Z1272α, LL-
Z1272β, and Ilicicolinic Acid A. Org Lett. 2016;18(19):5010-5013.
190. Saimoto H, Kusano Y, Hiyama T. A mild procedure for hydrolysis of alkoxymethyl aryl 
ethers to give hydroxyarenes. A rational synthesis of ascofuranone. Tetrahedron Lett. 
1986;27(14):1607-1610.
191. Fürstner A, Gastner T. Total Synthesis of Cristatic Acid. Org Lett. 2000;2(16):2467-
2470.
192. Marsico G, Pignataro BA, Masi M, et al. Asymmetric synthesis and structure-activity 
studies of the fungal metabolites colletorin A, colletochlorin A and their halogenates 
analogues. Tetrahedron. 2018;74(28):3912-3923.
Page 73 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
74
193. Kan T, Hashimoto M, Yanagiya M, Shirahama H. Effective deprotection of 2-
(trimethylsilylethoxy)methylated alcohols (SEM ethers). Synthesis of thyrsiferyl-23 
acetate. Tetrahedron Lett. 1988;29(42):5417-5418.
194. Luque-Ortega JR, Reuther P, Rivas L, Dardonville C. New benzophenone-derived 
bisphosphonium salts as leishmanicidal leads targeting mitochondria through inhibition 
of respiratory complex II. J Med Chem 2010;53:1788-1798.
195. Taladriz A, Healy A, Flores Pérez EJ, et al. Synthesis and structure-activity analysis of 
new phosphonium salts with potent activity against African trypanosomes. J Med Chem. 
2012;55(6):2606-2622.
196. Cortes LA, Castro L, Pesce Br, et al. Novel Gallate Triphenylphosphonium Derivatives 
with Potent Antichagasic Activity. PloS one. 2015;10(8):e0136852.
197. Long TE, Lu X, Galizzi M, Docampo R, Gut J, Rosenthal PJ. Phosphonium lipocations 
as antiparasitic agents. Bioorg Med Chem Lett. 2012;22(8):2976-2979.
198. Ross MF, Da Ros T, Blaikie FH, et al. Accumulation of lipophilic dications by 
mitochondria and cells. Biochem J. 2006;400(1):199-208.
199. Dardonville C, Alkhaldi AAM, De Koning HP. SAR Studies of Diphenyl Cationic 
Trypanocides: Superior Activity of Phosphonium over Ammonium Salts. ACS Med Chem 
Lett. 2015;6(2):151-155.
200. Dahal K, Martyn GD, Alber NA, Vanlerberghe GC. Coordinated regulation of 
photosynthetic and respiratory components is necessary to maintain chloroplast energy 
balance in varied growth conditions. J Exp Bot. 2017;68(3):657-671.
201. Munday JC, Settimo L, de Koning HP. Transport proteins determine drug sensitivity and 
resistance in a protozoan parasite, Trypanosoma brucei. Front Pharmacol. 2015;6:32.
202. Lüscher A, de Koning HP, Mäser P. Chemotherapeutic strategies against Trypanosoma 
brucei: Drug targets vs. drug targeting. Curr Pharm Design. 2007;13(6):555-567.
203. De Koning HP. Uptake of Pentamidine in Trypanosoma brucei brucei is Mediated by 
Three Distinct Transporters: Implications for Cross-Resistance with Arsenicals. Mol 
Pharmacol. 2001;59(3):586-592.
204. de Koning HP, Anderson LF, Stewart M, Burchmore RJ, Wallace LJ, Barrett MP. The 
trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 
purine transporter: additional insights on diamidine resistance in african trypanosomes. 
Antimicrob Agents Chemother. 2004;48(5):1515-1519.
205. Ward CP, Wong PE, Burchmore RJ, de Koning HP, Barrett MP. Trypanocidal 
Furamidine Analogues: Influence of Pyridine Nitrogens on Trypanocidal Activity, 
Transport Kinetics, and Resistance Patterns. Antimicrob Agents Chemother. 
2011;55(5):2352-2361.
Page 74 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
75
Page 75 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
76
Biosketches
Christophe Dardonville graduated in Chemistry (1993) at the Université Pierre et Marie Curie 
(UPMC, Paris VI) and obtained his Master Degree in Chemistry (D.E.A.) at the University of 
Montpellier, France, in 1994. He moved to Spain with a Marie Curie Fellowship and obtained his 
PhD degree in Chemistry (2000) from the Complutense University of Madrid. He was a 
postdoctoral fellow with Dr. Ian Gilbert (Welsh School of Pharmacy, Cardiff University, UK, 
2000–2003) and Dr. Nadine Jagerovic (IQM–CSIC, Madrid, 2003–2004). In 2004, he was 
appointed Senior scientist at the mixed research unit Lilly-Barcelona Science Park (2004–2005). 
Since 2006, he is appointed to the staff at the Medicinal Chemistry Institute (IQM) from the 
Spanish Council for Scientific Research (CSIC) in Madrid. As member of the group 
“Antiparasitic Chemotherapy”, his current research focuses on the design and synthesis of new 
drugs for parasitic neglected tropical diseases (trypanosomiases, leishmaniasis, malaria). In 
particular, his group is interested in the development of antiparasitic compounds targeting the 
unique mitochondrion of protozoan parasites. 
Harry de Koning is the Professor of Parasite Biochemistry and Pharmacology at the University 
of Glasgow and has been a Principal Investigator there since 1999, following a lectureship at the 
University of Glasgow and postdoctoral research positions at the University of Kent at Canterbury 
and the University of Iowa. He holds a Bachelor degree in Chemistry (1985), an MPhil in 
Biochemistry (1988) and a PhD in Biology (1992). Prof. De Koning is a leading researcher in 
chemotherapy of protozoa, most of all Trypanosoma species, and is considered a world-leading 
expert in drug delivery/transport in trypanosomes, drug resistance mechanisms, and the 
investigation of drug mode-of-action in protozoa. He is and has been part of multiple important 
research consortia in drug development, including PDE4NPD (10-member EU/FP7 consortium 
on new PDE inhibitors as antiparasitics), Nanotryp (EU/FP7 consortium using 
nanobodies/nanotechnology in antiparasite control), the Consortium for Parasitic Drug 
Development (CPDD, BMGF-funded international consortium that developed new sleeping 
sickness drugs and conducted the first clinical trial for this disease in decades), and in addition 
specific antiparasitics funding from the GlaxoSmithKline Open Lab Foundation, Otsuka 
Pharmaceuticals, the Wellcome Trust, The Medical Research Council and the Global Alliance for 
Livestock Veterinary Medicine (GALVmed) among others. He headed the working group on drug 
delivery strategies for the recent COST Action ‘Targeted chemotherapy towards diseases caused 
by endoparasites’. He currently has a publication list of 130 items with an H-factor of 32.
Page 76 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
77
Godwin Ebiloma is a graduate of Biochemistry from Kogi State University, Nigeria (2006). He 
obtained his Master Degree in Biochemistry with distinction from the Ahmadu Bello University 
in 2009. He was employed by the department of Biochemistry, Kogi State University, as Graduate 
Assistant in February 2009, before rising to the rank of Lecturer. He won a PhD scholarship from 
the Tertiary Education Trust Fund (TETFund) in 2013, and obtained a PhD in Infection and 
Immunity from the Institute of Infection, Immunity and Inflammation, College of Medical, 
Veterinary and Life Sciences, University of Glasgow in 2017. Following his graduation in 2017, 
he worked briefly as a Research Assistant at Strathclyde Institute of Pharmacy and Biomedical 
Sciences in the laboratory of Prof David Watson, before moving to Kyoto Institute of Technology 
(KIT) in the same year to accept a postdoctoral research fellowship from the Japan Society for 
the Promotion of Science (JSPS). He is presently a JSPS postdoctoral research fellow in the 
laboratory of Prof S. Harada and Prof T. Shiba at KIT. The two major aspects of his research are 
the investigation of molecular targets in parasites including the Trypanosome alternative oxidase, 
and chemotherapy against various protozoan parasites including, although not exhaustive, various 
species of Trypanosoma, Plasmodium, and Leishmania.
Emmanuel Oluwadare Balogun is a young scientist with research focus on Biochemical and 
Molecular Parasitology. He obtained BSc (2001) and MSc (2005) degrees in Biochemistry from 
Ahmadu Bello University (ABU), Zaria, Nigeria. During this period, he was supervised by late 
Professor Andrew Jonathan Nok (1962 - 2017) to investigate the pathogenesis of anemia in 
animals infected with Trypanosoma congolense. He became a staff in the Department of 
Biochemistry, ABU (2005). Emmanuel passed the examinations for the award of Japanese 
Government Scholarship and the entrance examinations for The University of Tokyo (UT), Japan. 
He was accepted into the Graduate School of Medicine, for a PhD program under the supervision 
of Professor Kita Kiyoshi, in the Department of Biomedical Chemistry (2007-2011). Dr. Balogun 
acquired expertise in X-ray crystallography during his PhD studies, and on completion, he became 
a Postdoc under a grant provided by SBI Pharma to investigate the potential use of 5-
aminolaevulinic acid for the treatment of malaria. In 2012, he was selected for a Postdoctoral 
Fellowship by the Japan Society for the Promotion of Science and he worked under Professors 
Harada Shigeharu and Kita Kiyoshi in Kyoto Institute of Technology (KIT) and UT, Japan, to 
elucidate the reaction mechanism of ATGK and contributed to determine the 3-D structure of the 
trypanosome alternative oxidase. He returned to his position in ABU as a Lecturer (2016), and 
serves as a Visiting Researcher to the Department of Biomedical Chemistry, UT and Department 
of Applied Biology, KIT, Japan. Dr. Balogun is interested in the development of new therapeutics 
for Africa-endemic diseases.
Page 77 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
78
 
Eduardo José Cueto Díaz graduated in Chemistry (2007) at the Autonomous University of Madrid 
(UAM) and obtained his master’s degree in chemistry (D.E.A.) at the King Juan Carlos 
University, Spain, in 2010. He moved to France in 2011 with a Marie Curie Fellowship and 
obtained his PhD degree in Chemistry (2014) from the Université de Bordeaux under the 
supervision of Dr. Mireille Blanchard-Desce, where he focused on the synthesis of new organic 
nanomaterials (organic nanodots) as tools for cell imaging. Following his PhD, he remained as a 
postdoctoral researcher at the Université de Bordeaux (2015-2016), which allowed him to expand 
his knowledge in the field. In 2017, he moved as a CNRS researcher to the University of 
Montpellier where he gained experience in the material science domain, by developing well-
defined and biocompatible functionalized porous silicon nanoparticles as a potential platform for 
cancer theranostic. Recently, he returned to Spain as a postdoctoral researcher in the group of Dr. 
Dardonville (IQM–CSIC) where he is working on the synthesis of new TAO inhibitors.
Page 78 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
79
Figure Legends
Figure 1. A scheme of aerobic (a) and anaerobic (b) glycolysis in bloodstream-form 
Trypanosoma brucei. The solid lines represent reactions catalysed by a single enzyme, whereas 
the dashed lines represent multiple sequential reactions. G-6-P = glucose-6-phosphate; F-1,6-BP 
= fructose-1,6-bisphosphate; GA-3-P = glyceraldehyde-3-phosphate; 1,3-BPG = 1,3-
bisphosphoglycerate; 3-PG = 3-phosphoglycerate; DHAP = dihydroxyacetone phosphate; G-3-P 
= glycerol-3-phosphate; 1 = Glycerol-3-phosphate dehydrogenase; 2 = Glycerol kinase; 3 = 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH); 4 = Glycerol-3-phosphate dehydrogenase 
(G-3-PDH).
Figure 2. Ki and IC50 values for the inhibition of the cyanide-insensitive terminal oxidase pathway 
(inhibition of oxygen uptake) of T. brucei, skunk cabbage, and mung bean by primary 
benzhydroxamic acids.55,117,124,150
Figure 3. Ki values for the inhibition of the AOX pathway (inhibition of oxygen uptake) of T. 
brucei by secondary benzhydroxamic acids.124 
Figure 4. Ki values for the inhibition of T. brucei alternative oxidase pathway (inhibition of 
oxygen uptake) by heterocyclic N-hydroxy compounds. IC50 value for the inhibition of T. vivax 
AOX.123,124,155
Figure 5. Ki and IC90 values for the inhibition of T. brucei alternative oxidase pathway (inhibition 
of oxygen uptake) by alkyloxybenzhydroxamic acids and related compounds.123
Figure 6. SAR of benzhydroxamic acid derivatives
Figure 7. Ki values for the inhibition of T. brucei alternative oxidase pathway (inhibition of 
oxygen uptake) by iron chelators: tropolone (65–69), 8-hydroxyquinoline (70–72), and pyridine 
derivatives (74–76).124
Figure 8. Ki and IC90 values for the inhibition of T. brucei alternative oxidase pathway (inhibition 
of oxygen uptake) by benzoic acid derivatives.125 IC50 values for the inhibition of purified 
rTAO.13,126
Figure 9. SAR of benzoic acid derivatives
Figure 10. Ki and IC90 values for the inhibition of the alternative oxidase pathway (inhibition of 
oxygen uptake) in T. brucei13,125,126 and munk bean156 by benzoate derivatives. IC50 values for the 
inhibition of purified rTAO.
Figure 11. (A) Ki and IC90 values for the inhibition of T. brucei alternative oxidase pathway 
(inhibition of oxygen uptake) by 3,4-dihydroxybenzoate, 3,4-dihydroxybenzamide, and 2,4-
dihydroxybenzoic acid derivatives. IC50 values for the inhibition of purified rTAO. (B) SAR and 
binding orientation of benzoate and benzamide derivatives with large R1 alkyl substituents. 
Page 79 of 81
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
80
Figure 12. Ki values for the inhibition of the alternative oxidase pathway (inhibition of oxygen 
uptake) by miscellaneous phenol derivatives125,156
Figure 13. IC50 values for the inhibition of purified rTAO by 4-hydroxybenzoate derivatives.13
Figure 14. Ki and IC90 values for the inhibition of T. brucei alternative oxidase pathway 
(inhibition of oxygen uptake) by benzaldehyde and keto derivatives. IC50 values for the inhibition 
of purified rTAO.113,125,126,159
Figure 15. 3-chloro-4-hydroxybenzonitrile derivatives: influence of tail hydrophilicity and 
methylene chain length on rTAO inhibition.159,160
Figure 16. Ki values for the inhibition of T. brucei alternative oxidase pathway (inhibition of 
oxygen uptake) by ubiquinol analogues.164
Figure 17. SAR of ascofuranone (AF): modification of the aromatic head. IC50 values for the 
inhibition of purified rTAO.10,59 
Figure 18. SAR of ascofuranone: modification of the aliphatic tail. IC50 values for the inhibition 
of purified rTAO.10,59
Figure 19. SAR of colletochlorin B (CCB). IC50 values for the inhibition of purified rTAO 
reported by West et al159,160 and Saimoto et al59 (left and right IC50 values, respectively).
Figure 20. SAR of ilicicolin derivatives. IC50 value for the inhibition of T. vivax AOX.
Figure 21. Ramachandran Plot statistics for TAO-CCB (PDB ID: 3W54). PROCHECK was used 
to prepare and assess the quality of the TAO structure data and for its suitability for use in SADD. 
93.3% of the residues were in most favored regions, 6.7% in additional allowed regions, and none 
in generously allowed and disallowed regions (0.0%). The statistics reveals that the structure is 
above the acceptable accuracy cut-off of 90%, hence, may be useful for SADD.
Figure 22. X-ray crystal structure of TAO. Long α-helices are labeled αL, while short helices are 
labelled αS. Diiron and hydroxo atoms are shown as spheres. (A) Cartoon representation of the 
dimeric structure viewed roughly parallel to the helix axes. Helices are shown as ribbons. Chain 
A is rainbow-colored while chain B is colored cyan. Each monomer consists of six long helices 
(αL1 – αL6 in chain A, αL1’ – αL6’ in chain B) and four short helices (αS1 – αS4 in chain A and 
αS1’ – αS4’ in chain B). Except for the N-terminal arm, each monomer is shaped as a compact 
cylinder. Horizontal beige bars depict the two leaflets of the inner mitochondrial membrane, 
where residues of αL1, αL4 and portions of αL2 and αL5 form the membrane-anchoring base. (B) 
Membrane side of the monomers. Length of the long helices could be visualized to appreciate the 
broad surface formed by αL1 and αL4 for membrane interaction. (C) Dimer formation. Two 
monomer chains A and B intimately associated to form the functional dimer of TAO. Chain A is 
represented as cartoon while chain B as surface model. The monomers ‘hug’ each other with their 
long N-terminal arm where the short helices are located, additionally, helices αL2, αL3, and αL4 
participate in the dimerization. (D) A zoom-in on the diiron center. The diiron center is created 
by six amino acid residues, Glu123, Glu162, His165, Glu213, Glu266, and His269. Two iron ions 
(Fe1 and Fe2 shown as green spheres) are ligated by the glutamate residues via coordinate bonds 
(shown as solid lines). Iron ion Fe1 directly coordinates the hydroxo group in the diiron center. 
The histidine residues participate in the stabilization of the diiron center by forming hydrogen 
bonds with the glutamate residues. 
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Figure 23. Structure of TAO-inhibitor complex. (A) Complex structure of TAO (cyan sticks)  
bound with ascofuranone derivative AF2779-OH (yellow stick); the structure is superposed with 
the diiron center of the uninhibited form (green sticks). The diiron and hydroxo of the inhibited 
form are brown and blue spheres, respectively. While the diiron and hydroxo of the uninhibited 
form are green and yellow spheres, respectively. The inhibitor is bound in the active site of TAO 
close to the diiron center. Binding of the inhibitor caused a displacement of the Fe1, the Fe2 is 
not affected. (B) Model structure of SHAM derivative 322. 
Figure 24. (A) Structural features of ascofuranone (188). (B) Ascofuranone pharmacophore: 
functional interaction between AF and AOX.59 Dash-lines represent H-bonds with amino acids of 
the inhibitor binding site.
Figure 25. Schematic representation of uptake and accumulation of mitochondria-targeted 
triphenylphosphonium (TPP) TAO-inhibitor conjugates within BSF trypanosomes. ΔΨp, plasma 
membrane potential; ΔΨm, mitochondrial membrane potential.
Figure 26. IC50 values for inhibition of purified ΔMTS-TAO and EC50 values against T. b. brucei 
(WT) by 4-hydroxybenzoate–lipocation (LC) conjugates (292–305), 4-alkoxybenzaldehyde–LC 
conjugates (306, 307), and (3)4-alkoxybenzoate–LC conjugates (308–322). The IC50 of SHAM 
(2) is 5.93 µM in this assay.13,62,126 TPP: triphenylphosphonium. Quin: 1-quinolinium.
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